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Thesis overview 
Cancer survivorship is increasing worldwide as a result of improvements in treatment 
and earlier diagnosis and prevention (1). Yet not only do cancer survivors continue to 
experience adverse physical and psychological effects from the illness (2-4), those who are 
close to them, particularly their caregivers and partners, also report significant psychological 
difficulties. These include increased levels of anxiety, depression and worries that the cancer 
may return. Examining the psychological mechanisms underpinning anxiety, depression and 
fear of cancer recurrence (FCR) in partners of cancer survivors is critical to the development 
of psychological interventions for this population. 
The first chapter in this thesis is a systematic review that aimed to narratively 
synthesise cross-sectional and longitudinal studies that have measured demographic, clinical 
and psychosocial correlates and predictors of FCR. This was selected as although two 
reviews have examined FCR in caregivers (2, 5), there has been no systematic synthesis of 
studies assessing correlates and predictors of caregivers’ FCR. 
The second chapter in this thesis is an empirical paper that investigated, for the first 
time, the utility of a transdiagnostic psychological model of emotional distress, the Self-
Regulatory Executive Function (S-REF) model (6), for understanding emotional distress 
experienced by adult partners of adult cancer survivors. The aim of this study was to test 
whether metacognitive beliefs (beliefs about thoughts) were associated with FCR, anxiety 
and depression in partners of cancer survivors, whilst controlling for demographic and 
clinical variables. 
Both the review and empirical paper were prepared for submission to Psycho-
Oncology and have been formatted in line with the author guidelines (Appendix A). This 
journal was chosen as it focuses on the psychological aspects related to cancer and is 
concerned with the psychological responses of families and caregivers to cancer. The 
 
 
 
2 
findings from the review and empirical paper have potential clinical implications for future 
development of psychological interventions for caregivers of cancer survivors. 
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Abstract 
Objective: Fear of cancer recurrence (FCR) is a significant concern for family caregivers of 
cancer survivors and is associated with various adverse outcomes, including increased 
emotional distress and poorer quality of life. Although several theoretical models have been 
proposed to account for FCR in cancer patients and survivors, their applicability to caregivers 
is unknown. The aim of this review was to identify clinical, demographic and psychological 
factors that are associated with, and predict, FCR in caregivers of cancer survivors. Method: 
AMED, CINAHL, Medline, PsycINFO and Scopus were systematically searched for relevant 
studies. Studies were included if they reported quantitative data on factors associated with 
FCR or similar constructs (e.g., worry or anxiety about cancer recurrence) in family 
caregivers of adult cancer survivors. Included studies were assessed for methodological 
quality using a standardised checklist. Results: Sixteen studies, half of which were cross-
sectional, were included and summarised narratively. Non-modifiable factors, including age 
and treatment modality were consistently associated with increased FCR. Significant positive 
associations were also reported between illness perceptions and FCR. However, small 
numbers of studies reported on each of the demographic, clinical and psychological factors. 
There were also several methodological limitations to the included studies, as half of the 
studies were cross-sectional, and most reported data from the USA. Conclusions: Research 
examining FCR in caregivers of cancer survivors has predominantly focused on demographic 
and clinical factors. Given the paucity of research exploring the psychological mechanisms of 
FCR, future research should investigate theoretical underpinnings of FCR in caregivers of 
cancer survivors to support the development of psychological interventions for this 
population.  
 
Keywords: Cancer survivors, family caregivers, fear, recurrence, systematic review 
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1. Introduction 
  
The number of new cancer diagnoses in England is increasing each year, with incidence 
rates in the United Kingdom now ranked higher than two-thirds of Europe (1). Yet despite 
the increase in diagnosis, cancer survival rates in the United Kingdom have doubled in the 
last 40 years, with approximately half of people diagnosed with cancer in England and Wales 
now surviving for 10 years or more post-diagnosis (2, 3). Comparable results have been 
demonstrated world-wide (Australia, Canada, Denmark, Ireland, New Zealand, Norway), 
whereby 1-year and 5-year survival rates have increased across almost all cancer types (4). 
Although improvements in health care have led to earlier diagnosis and more effective, 
targeted medical treatment (4), family caregivers of survivors continue to experience adverse 
effects of the illness, both physically and psychologically (5-7). Specifically, cancer 
caregiving responsibilities can result in issues such as pain, fatigue, financial difficulties and 
social isolation (7, 8). 
One of the most distressing concerns for survivors and their families is fear of cancer 
recurrence (FCR) (9), defined as “fear, worry, or concern about cancer returning or 
progressing” (10). Prevalence of FCR is estimated to range between 39 and 97% in cancer 
survivors (11), and is thought to remain stable over time, persisting even after completion of 
acute medical treatment (11-13). Prevalence rates of FCR are also high in family caregivers 
(14) and, in some cases, can be higher than for the patients themselves (15, 16). Managing 
worries about cancer returning is a commonly-reported unmet need for caregivers (17-19), 
which is associated with elevated emotional distress (16) and poorer quality of life (QoL) 
(11). 
Various theoretical models have been proposed to account for the psychological 
mechanisms underpinning FCR in cancer patients and survivors. These include the Common 
Sense Model (CSM; 20), the Self-Regulatory Executive Function (SREF; 21) model and 
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Social-Cognitive Processing Theory (SCPT; 22). The CSM (20) suggests that internal and 
external cues activate cognitive responses associated with FCR. In contrast, The S-REF 
model (21) argues that the development and maintenance of emotional distress is driven by 
cognitive processes rather than the content of thoughts themselves, whereas the SCPT (22) 
proposes that the social environment can act to either encourage or deter cognitive processing 
of the cancer experience. 
It is argued that many of the theoretical frameworks used to understand FCR in cancer 
survivors consist of similar components, including internal (e.g., physical symptoms, 
treatment side effects) and external (e.g., clinical follow-up) cues that trigger a cognitive 
response associated with FCR (23). Following an appraisal of such cues, a variety of coping 
responses, some less helpful than others, are implemented which are influenced by the social 
environment and other contextual factors (23, 24). Such coping responses may include 
avoidance, limited future planning, symptom checking and misinterpretation of symptoms, 
and reassurance seeking from health professionals and family members, which in the longer 
term can increase FCR (24).  
More recently, a blended model of FCR (25) has been developed which incorporates the 
CSM and Uncertainty in Illness Theory (26). As FCR is deemed to share similarities with 
worry (9), the blended model also comprises of cognitive theories of worry (27-29). It argues 
that reduced tolerance for uncertainty and metacognitions (beliefs about thoughts) are key 
factors in the maintenance of worry. Findings from this model indicate that triggers, 
perceived risk of recurrence, and illness uncertainty predict survivor FCR, whilst positive 
beliefs about worrying and intolerance of uncertainty do not directly predict FCR but act 
indirectly by increasing maladaptive coping (25, 30). 
Psychological interventions for FCR in patients have been predominantly based on 
cognitive behavioural approaches to address the behavioural and psychological responses of 
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unhelpful coping responses (23, 24). Yet, in line with the assumptions proposed by the 
blended model of FCR (25), interventions that focus on cognitive processing and 
metacognitions in FCR, such as worry, rumination or attentional bias, rather than the content 
of thoughts, have been to found to be more effective in comparison to traditional cognitive 
behavioural approaches (31). Certain components from interventions including metacognitive 
therapy and acceptance and commitment therapy may be appropriate for targeting such 
processes (32). 
Similar to cancer survivors, caregivers often engage in unhelpful coping responses such 
as avoidance of cancer-related discussions, reluctance to make plans for the future and 
reassurance seeking (30, 33). Furthermore, although caregivers do not experience internal 
cancer-related cues, it is argued that the cancer journey is experienced by the family as a 
whole (34). Therefore, caregivers are likely to be aware of survivors’ physical experiences of 
cancer diagnosis and treatment, through helping patients to manage symptoms and treatment 
side effects (33). Furthermore, caregivers are exposed to an array of external cues and 
situations which may trigger FCR, including cancer-related conversations, media references 
to cancer, appointments with health professionals and survivors’ follow-up appointments and 
feeling unwell themselves (35). Models of FCR in cancer survivors may therefore be 
applicable to understanding FCR in caregivers. However, it is currently unclear if similar 
components are relevant in relation understanding FCR experienced by caregivers of cancer 
survivors, or indeed, if there are other factors which are significant in the development of 
FCR in this population.  
In order to develop more effective interventions for this group, we need to better 
understand the psychological processes underpinning FCR. Although two reviews have 
examined FCR in caregivers (11, 36), no systematic synthesis of studies examining correlates 
and predictors of caregivers’ FCR exists. This systematic review aims to address this need by 
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critically appraising and synthesise the findings of quantitative studies investigating 
demographic, clinical and psychosocial correlates or predictors of FCR in family caregivers 
of adult cancer survivors. Areas for further research, clinical implications and areas of 
intervention will be outlined.  
2. Method 
2.1 Review conduct and reporting 
Review conduct and reporting adheres to recommendations by the Centre for Reviews 
and Dissemination (37) and Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidance (38). The protocol was registered on the international 
prospective register of systematic reviews, Prospero, in January 2019 (reg. number 
CRD42019119729) and can be accessed at https://www.crd.york.ac.uk/PROSPERO.  
 
2.2 Search strategy 
AMED, CINAHL, Medline, PsycINFO and Scopus were systematically searched for 
published literature using the following search terms: partner (partner*, couple*, spous*, 
dyad*, carer, caregiver, care-giver, care giver, caregiv*, husban*, wife or wives) and (fear* 
or worr* or anxiet* or concer* or afraid) and (recur* or relaps* or reoccur* or return* or 
progress*) and (cancer* or tumor* or tumour*). There were no restrictions placed on 
publication date. Searches were repeated in March 2020 to identify any new publications 
relevant to the review question. 
 
2.3 Inclusion and exclusion criteria 
To be included in the review, studies had to report quantitative data on factors 
associated with FCR or similar constructs (e.g., worry or anxiety about cancer recurrence) in 
adult family caregivers (partners, family members and close friends) of adult cancer survivors 
(both aged ≥18 years). Patients were classed as cancer survivors if they had received a 
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diagnosis of cancer at least 6 months ago, had completed acute medical treatment for cancer 
and had not been diagnosed with a secondary cancer. Articles had to be published in English 
in a peer-reviewed journal. Studies were excluded if cancer patients had not yet received 
treatment, in order to ensure findings were deemed to be taken from a survivorship phase. 
Studies which did not report data separately for cancer survivors were also excluded (e.g. 
studies reporting data from survivors and patients with metastatic disease). All case studies, 
commentaries, conference abstracts, dissertations, editorials, qualitative studies and review 
articles were excluded. 
 
2.4 Study selection 
Two reviewers (LOR and AW) independently assessed the titles and abstracts of 
potentially relevant papers. The reviewers then independently reviewed the full-text papers 
against the inclusion and exclusion criteria. Papers which did not meet the inclusion criteria 
were removed. Discrepancies were discussed with the wider research team (MGC, PF, SC) 
until a negotiated conclusion was reached. 
 
2.5 Data extraction 
For each study, relevant demographic, methodological and summary data were 
extracted using a standardised data extraction form (Appendix B) by LOR and independently 
checked for accuracy by AW. Disagreement or uncertainty was resolved through discussion 
with the wider research team. Authors were contacted if data were unclear or had not been 
reported within the paper (Appendix C). The following information was extracted: (i) author, 
(ii) year of publication, (iii) study design, (iv) clinical and treatment characteristics of the 
survivor (diagnosis, stage, time since diagnosis and treatment type), (v) caregiver 
demographics, (age, gender, ethnicity and relationship length), (vi) main findings, including 
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correlates and predictors of FCR. Where studies reported multiple analyses, only data from 
the most complex relevant multivariate analyses were extracted. Studies that reported data 
from the same larger database, but focused analyses on different outcomes were interpreted 
and referred to as separate studies, with their linked status noted. 
  
2.6 Risk of bias 
Studies were assessed for risk of bias using a quality appraisal tool adapted from the 
Agency for Healthcare Research and Quality (Appendix D) (39), which assesses risk of bias 
in studies across various domains relevant to research with physical health populations. This 
tool was considered appropriate to use in this review as it considers risk of bias across key 
methodological areas, such as sample selection, size, description, handling of missing data 
and analysis (40), thus allowing for comparison of studies across domains. Two reviewers 
(LOR and AW) separately assessed risk of bias in the included studies. Uncertainty was 
resolved through discussion with the wider research team (MGC, PF, SC). In line with Centre 
for Reviews and Dissemination (37) guidance, studies were not excluded based on outcome 
of the risk of bias assessment.  
 
3 Results 
The search strategy identified 1729 potentially relevant records. After exclusion of 
duplicates and screening of titles and abstracts, 40 potentially eligible articles remained. After 
reviewing their full-text, 8 articles, reporting 7 studies, were identified for inclusion for 
review. Nine studies were identified during the updated search, resulting in the inclusion of 
19 articles, reporting 16 studies*. The process of identification of papers to inclusion for 
 
* The samples of Janz et al. (41), Soriano et al. (42), Soriano et al. (43), Soriano et al. (44) and Perndorfer et al. 
(45) were drawn from a larger database (SEER). Soriano et al. (43) and Soriano et al. (44) used the same sample 
and therefore will be considered as one study. Janz et al. (41), Soriano et al. (42) and Perndorfer et al. (45) studied 
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review is summarised in Figure 1. Various areas, including demographic, clinical and 
psychosocial factors, were examined in the studies and are summarised in Table 1. 
 
3.1 Study characteristics 
The main characteristics of the studies are displayed in Table 2. Nine studies, reported 
in 12 articles, were conducted in the USA (41-45, 48-54). The remainder were conducted in 
Taiwan (55), UK (46, 47, 56), Ireland (57), The Netherlands (58) and China (59). Studies 
used a convenience or purposive sampling strategy and were either cross-sectional (41, 42, 
46, 48-53, 57, 58) or longitudinal surveys (42-45, 47, 54-56, 59). Seven studies recruited 
patients with breast cancer, four with head and neck cancer, three with prostate cancer, and 
two with mixed cancer diagnoses. The shortest time since diagnosis or treatment was 90 days 
(54), whilst the longest time was 7.3 years (SD 3.6) (49).  
Out of the 16 studies, nine focused on partners (41-45, 50, 54, 55, 58, 59), whilst seven 
studies reported data on caregivers, including other family members and friends. Caregivers 
were predominantly White, female and middle-aged. Education level varied across studies, 
with college or above tending to be the most commonly reported education level. 
Relationship length varied, with the longest mean length of relationship between caregiver 
and survivor being 43.0 years (range 8-57 years) (58) and the shortest being 24.40 years (SD 
13.8) (42).  
Eight studies, reported in nine articles, compared the mean FCR scores of survivors and 
caregivers. Of these, five studies, reported in 6 articles found that carers had significantly 
 
non-overlapping samples, thus will be interpreted and referred to as separate studies. Similarly, samples of 
Dempster et al. (46) and Graham et al. (47) were drawn from a larger study (OPA, UK) but will be interpreted as 
separate studies as they used non-overlapping samples. Mellon and Northouse (48) Mellon et al., (2006, 2007, 
2001) were based on data from the MDCSS database and used the same sample, therefore will be considered as 
one study. 
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greater levels of FCR than survivors (41, 52-54, 56, 58); whilst one study found that patients 
reported significantly higher FCR than spouses (44). 
 
3.2 Results of assessment of risk of bias 
The risk of bias assessment results are outlined in Table 3, which indicate that the 
majority of areas, including unbiased selection of cohort, validated measures of outcome and 
dependent variables, and appropriate analyses rated highly. Several limitations were 
identified in relation to study design, assessment of FCR and justification of sample sizes. 
Only five studies reported a sample size calculation (51, 52, 56-58). Out of the 16 studies, 
only nine studies were found to report an adequate follow-up period. However, half of the 
studies included for review were cross-sectional therefore could not be assessed against the 
adequate follow-up criteria. Most studies provided adequate descriptions of the study cohort, 
but three studies underreported demographic data (46, 47, 59). Most used validated methods 
for assessing predictor variables; however, in one study (43), it was not clear if the measures 
used had been validated. Most studies used validated measures of assessing FCR; however, in 
four studies (41, 51, 54, 59), it was unclear if adapted measures had been validated. In one 
study, it was not clear if confounding demographic variables had been controlled for in 
analyses (55).  
 
3.3 Fear of cancer recurrence 
Most studies found that caregivers experienced moderate levels of FCR, however, three 
studies, reported in four articles, reported very low levels of FCR (42-45). One study found 
that 49% of partners had high levels of FCR and 57% of highly fearful partners were in a 
relationship with a highly fearful survivor (58). Furthermore, prospective studies reported 
that caregiver FCR remained stable over time, ranging from six months to three years post-
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treatment (47, 54, 56). Of these, one study used an adapted measure of FCR (54), thus it is 
unclear if this is a validated instrument. The remainder used validated measures of FCR (47, 
56). 
 
3.4 Demographic factors 
Data indicated support for significant associations between age and FCR. Twelve 
studies, reported in 13 articles, examined the relationship between age and FCR. Of these, 
one study found a weak negative association between age and FCR (r = -.17) (51) whilst five 
studies reported a significant association which remained significant when other clinical and 
demographic variables were controlled for  (42, 46, 53, 57, 58). However, there were no 
details regarding cancer stage and treatment type in one of these studies (46). Four studies 
assessed the relationship between gender and FCR, one of which found a significant weak 
association between gender and FCR, with female carers reporting higher FCR than male 
carers (57). Of the three studies that assessed the relationship between ethnicity and FCR, 
only one found a significant relationship, reporting that Latino partners were significantly 
more likely to worry than White partners, whilst Black partners were less likely to report 
worry (41). However, as this study used an adapted FCR measure, it is not clear if this has 
been validated.  Seven studies assessed the relationship between education and FCR. Of 
these, one study found a very weak negative association between education and FCR (r = -
.16) (50), however as there is no evidence of a sample size calculation, it is unclear if the 
study is sufficiently powered.  
 
3.5 Clinical factors 
3.5.1 Time since diagnosis and treatment 
There was limited support for significant associations between time since diagnosis 
and FCR. Two out of the eight studies that assessed the relationship between time since 
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diagnosis and FCR found that those caring for more recently diagnosed survivors reported 
higher FCR (49, 57) which remained significant when controlling for other demographic and 
clinical factors (57). Of these studies, one study met all of the quality assessment criteria 
(57), however sample size calculation was not reported in Boehmer et al. (49)’s study, which 
may indicate issues regarding statistical power and potential for Type I errors. 
 
3.5.2 Cancer stage and severity 
Seven studies explored the relationship between cancer stage and FCR, none of which 
found a significant association (41, 49, 51, 53, 55-57). One study assessed the relationship 
between cancer severity and FCR, and found a significant positive association when 
controlling for other demographic and clinical variables (51). However, as this study used an 
adapted FCR measure, it is unclear if this has been validated. 
 
3.6 Comorbidities 
Limited support was found for significant associations between comorbidities and 
FCR. Of the five studies that assessed the relationship between comorbidities and FCR, two 
found that greater number of comorbidities resulted in higher FCR when controlling for other 
variables, specifically survivor comorbidities (49) and caregivers’ own reported number of 
comorbidities (41). One study examined the relationship between FCR and survivor’s 
physical health and found that increased caregiver FCR was associated with poorer physical 
health of survivors (51). 
3.6.1 Treatment type 
Data demonstrated mixed support for significant associations between treatment 
modality and FCR.  Seven studies assessed the relationship between type of treatment and 
FCR. Of these, one study reported a very weak positive association between chemotherapy 
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and FCR (r = .14) (57), whilst three studies reported significant results which remained 
significant after controlling for other demographic and clinical variables (41, 49, 54, 57). 
Those caring for survivors who had received anti-oestrogen therapy (49) or chemotherapy 
(41, 57) reported higher FCR. Two studies found that those caring for survivors who had 
undergone major surgery were more likely to have lower FCR (54, 57). This finding was 
significant when controlling for other demographic and clinical variables at 6 months post-
treatment, but not at the 12 month time point (54). 
 
3.6.2 Medical follow-up 
One study, reported in two articles, used a three week diary to investigate the impact of 
a mammogram on FCR, which reported that there was a significant increase in FCR during 
days leading up to the mammogram, and avoidance of threatening stimuli was predictive of 
FCR on the day of the mammogram (44). However, it was not stated whether confounding 
demographic variables were controlled for in this analysis. Following the mammogram, 
partner responsiveness (response perceived as genuine and enthusiastic) predicted lower 
caregiver FCR, whilst patient capitalization attempts (disclosure of positive events) predicted 
greater FCR at week 3 (43). However, Soriano et al. (43) did not report sample size 
calculation, therefore findings may be at risk of Type I errors. 
 
3.7 Psychosocial factors 
3.7.1 Emotional distress 
There were significant associations found between level of anxiety and FCR. Three 
studies assessed the relationship between anxiety and FCR, all of which reported a weak 
positive association between anxiety and higher FCR (r = .24 to .39) (42, 44, 51). One study 
examined the relationship between emotional distress (anxiety and depression combined) and 
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FCR, and reported a strong positive association (r = .73) (56). One study examined the 
relationship between negative affect and FCR, which found that as spousal negative affect 
increased, so did FCR level (42). 
 
3.7.2 Interpersonal factors 
Data indicated mixed support for significant associations between survivors and 
family caregivers (Table 4). Nine studies, reported in ten articles, assessed the relationship 
between survivors and caregiver FCR. Of these, eight studies found weak to moderate 
associations between survivor and family caregiver FCR scores (r = .19 to .53) (42, 44, 45, 
48, 49, 51, 53, 58), which remained significant when controlling for other variables at 6 
months post-diagnosis (56). However, the quality of studies that report these findings are 
mixed, as six of the nine studies do not report a sample size calculation (42, 44, 45, 48, 49, 
53), whereas three studies did state this calculation (51, 56, 58). Consequently, it is unclear if 
the aforementioned studies are sufficiently powered and are potentially at risk of Type I 
errors.  
Two studies examined the association between relationship quality and FCR, with one 
study reporting a significant positive association which was also found in next-day FCR 
when measured over 21 days (42). Three studies, reported in five articles, assessed the 
relationship between social support and FCR. Of these, one study found that social support 
was significantly negatively associated with FCR when controlling for other variables (49). 
One study investigated the relationship between loneliness and FCR, reporting a weak 
positive association between loneliness and FCR (r = .27) (57). 
Five studies investigated the impact of communication on FCR, all of which found 
significant results. Specifically, on a day that partners perceived the cancer survivor to be less 
available or responsive to discussions of cancer-related worries, partners were more likely to 
have greater FCR on that same day, but not the next day (42). One study found that patient 
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disclosures of positive events resulted in decreased FCR as did partner responsiveness which 
was perceived to be genuine and enthusiastic (43). However, it is unclear if the adapted 
measure used to assess partner responsiveness is validated. Similar findings were reported 
whereby partners’ perceptions of positive information (e.g., supportive and inclusive ) and 
negative information (e.g., indifferent) resulted in a change in FCR (59). One study reported 
that cognitive processing mediated the relationship between social constraints and FCR (50). 
Attempting to protect one’s partner by hiding cancer-related concerns was weakly positively 
associated with increased FCR (r = .15) (45). 
 
3.7.3 Stress and coping 
Two studies, reported in four articles, assessed the relationship between stressors and 
FCR, all of which found significant results. Specifically, care-related stressors (financial 
impact and time-burden associated with caregiving) (57) were positively associated with 
FCR, whilst a weak positive relationship was reported between stressors related to ill health 
and FCR (r = .24 to .29) (48, 52, 53). 
Two studies assessed the relationship between coping strategies and FCR. Of these, 
one study reported a weak positive association between interpersonal coping (e.g., seeking 
support from cancer survivor) and FCR (r = .35) (46), whilst another study found that this 
association remained significant when other variables were controlled for (47). Although the 
latter study indicated a 40% drop out rate over time, there were no significant differences on 
depression or FCR between participants who provided complete data and those who provided 
data at one time point only (47). One study found that increased use of reflection and 
relaxation was a significant predictor of higher FCR at 12 months follow-up, whilst those 
with a hopeful and in-control outlook exhibited lower FCR (47). The authors suggest that the 
association between increased use of diversionary and relaxation coping skills and greater 
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anxiety may be indicative of such strategies reinforcing an aspect of avoidance, which may 
be beneficial in the short term but in the longer term, act to maintain anxiety. 
 
3.7.4 Quality of life 
Four studies, reported in five articles, assessed the relationship between QoL and FCR. 
All studies found a significant result, indicating a weak positive association between QoL and 
FCR (r = -.28 to .33) (48, 51, 52, 57). Specifically, higher FCR was linked to lower QoL 
scores, including poorer caregiver mental health (51), lower survivor QoL (57) and poorer 
family QoL (48, 52). One study found significant differences between health-related QoL in 
partners with high and low FCR, reporting that partners with high FCR obtained significantly 
lower scores on social functioning, emotional role functioning, mental health, vitality and 
general health (58). The majority of the studies that reported on QoL met the key criteria of 
the quality assessment and reported on relatively large sample sizes ranging from 123 – 455. 
 
3.7.5 Psychological mechanisms 
One study, reported in three articles, examined the relationship between the meaning of 
illness and FCR, reporting a weak negative association between negative meaning of illness 
and FCR (r = -.27 to -.28)  (48, 52, 53). Three studies assessed the relationship between 
illness perceptions and FCR, all of which reported significant findings (46, 47, 59). 
Specifically, one study found that an understanding of the disease was negatively associated 
with FCR, whilst belief of less serious consequences and control over condition were 
positively associated with FCR (46). One study reported that caregivers with a reduction in 
beliefs of severe consequences and causes of the condition, and an increase in control beliefs 
and understanding of the condition was associated with decreased FCR over a 12-month time 
period (47). One study found that over a 10 day period, spouses’ negative illness 
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representations were negatively associated with their own disclosures of positive information 
(59). However, this study did not state a sample size calculation therefore statistical analysis 
may be underpowered and at risk of Type I error rates. 
 
4 Discussion 
This review summarised cross-sectional and prospective research investigating the 
demographics, clinical and psychological factors associated with FCR in caregivers of cancer 
survivors. Sixteen studies, reported in 19 articles, were included and summarised narratively. 
Non-modifiable factors, including age and treatment modality were consistently associated 
with increased FCR. Although there was only limited research investigating psychological 
mechanisms (n = 3), significant associations were found between illness perceptions and 
FCR. Specifically, a good understanding of the cancer diagnosis was negatively associated 
with FCR, whilst belief of less serious consequences and control over the condition were 
positively associated with FCR. 
Caregivers reported moderate levels of FCR which appeared to remain stable over 
time (47, 54, 56). This is in line with the cancer survivorship literature, whereby review 
findings suggest that FCR can be experienced for five or more years after the initial diagnosis 
(13). Notably, findings indicated that caregivers reported significantly greater levels of FCR 
than survivors (41, 52-54, 56). Caregivers have commonly been found to experience greater 
psychological distress compared to patients (60-62). Therefore, it would appear that family 
caregivers would benefit from further intervention and support, given the prevalence of 
psychological difficulties highlighted in the literature. Additionally, a significant association 
was found between caregiver and survivor FCR (48, 51, 53, 56, 58). An interdependent 
relationship has also been found to exist between patients’ and caregivers’ emotional distress 
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(63, 64), and research has suggested that interventions aimed at reducing distress should be 
delivered jointly, as treating patients and caregivers together might be effective than treating 
the patient alone (65). Therefore, it would appear that there is an argument for delivering 
joint interventions to treat FCR. 
There were mixed findings with regards to demographic factors and level of FCR. 
Younger age was significantly associated with FCR (41, 42, 46, 51, 53, 57, 58), which has 
been commonly reported in the cancer survivorship literature and may be due to the 
unexpectedness of cancer in younger age and the perceived negative physical, social or 
economic impact of such a disease (66, 67). Limited significant outcomes were reported with 
regards to the remaining demographic factors. Similar findings have been reported in the 
cancer survivor literature, whereby no demographic, clinical or social factors reliably 
predicted subsequent distress in cancer survivors (68).  
Of the 13 studies that assessed the association between clinical outcomes and FCR, 
six reported significant associations between clinical outcomes and FCR. Time since 
diagnosis (49, 57) was significantly associated with higher FCR, which contrasts with the 
cancer survivorship literature (11, 13, 69). Four studies found that treatment modality was 
significantly associated with FCR, which is consistent with the cancer patient and 
survivorship literature that indicates that different treatment approaches are significantly 
associated with FCR (70-72). Patients who have had chemotherapy or radiotherapy are likely 
to experience side effects, and an increased number of hospital trips and inpatient episodes, 
which may contribute to psychological morbidity (73). Furthermore, research has indicated 
that some patients may choose more invasive surgeries even when the risk of recurrence is 
low, in order to eliminate risk to the greatest possible extent (74). Consequently, caregivers 
may perceive surgery as a more conclusive treatment, and therefore may be of the view that 
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the cancer is less likely to return, as opposed to treatment side effects and multiple hospital 
trips which may act as triggers of FCR.  
Only one study explored the association between clinical follow-up (mammogram) 
and FCR, which reported a significant association (44). This is consistent with research that 
suggests medical examinations and annual check-ups are triggers of FCR for cancer survivors 
(75, 76). It may be that cancer survivors who continue to have routine medical follow-up 
appointments report higher FCR, yet research also argues that survivors with high FCR 
schedule more frequent appointments to be feel more reassured (77). As caregivers often 
attend medical appointments with the survivor (33), it is likely that such follow-ups may also 
act as a trigger for FCR in caregivers. However, as only one study looked at clinical follow-
up, conclusions cannot be drawn. 
Two studies reported a significant association between comorbidities and caregiver 
FCR (41, 49). Similar findings have been reported in the cancer survivorship literature, with 
comorbidities found to be strongly associated with FCR (75, 78, 79). Internal physiological 
cues related to comorbid conditions may be misinterpreted as possible cancer recurrence, thus 
symptoms may act as a reminder of vulnerability and trigger FCR (20, 24, 69). For 
caregivers, they are likely to witness survivors expressing somatic concerns and reporting 
treatment side effects, therefore, caregivers may be more vigilant regarding changes in the 
survivors’ physical health which may exacerbate worries that the cancer might return. 
Furthermore, lack of communication between the dyad may lead to worry regarding somatic 
concerns and side effects (42, 50). Again, similarly to demographic factors, it would seem 
that clinical indicators are not as critical as psychological factors in the development and 
maintenance of FCR, and there are intrapersonal factors which need to be considered. 
There was a paucity of studies in the review that assessed psychological factors. Out 
of the psychosocial factors examined, communication appeared to have a significant impact 
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on FCR. The less someone was able to tell their partner about their cancer-related concerns, 
the more likely they were to experience FCR (42, 50). Research suggests that unsupportive 
partner behaviours (i.e., critical or avoidant responses) are associated with both patient and 
partner reports of hiding concerns and disengagement (80). One study reported that 
caregivers hiding their own cancer-related worries in an attempt to protect the survivor was 
associated with increased FCR (45), although this was a weak association and the study 
sample size was small. Similar findings have been highlighted in previous research, 
particularly caregivers’ reluctance to discuss emotions relating to cancer for fear of burdening 
or upsetting the patient (33, 81). Consequently, it would appear that communication between 
the caregiver and survivor is an important area for further research. 
The review findings indicated that caregivers relied on various coping strategies, 
including reflection, relaxation, diversion and interpersonal approaches (e.g., through 
requiring frequent reassurance regarding FCR), which were significant predictors of higher 
FCR (46, 47). Reassurance seeking and avoidance are common behavioural manifestations of 
FCR in cancer survivors (24, 25, 82). Research also highlights that caregivers engage in a 
high use of avoidance, distraction and denial (30, 83), yet acknowledge that such strategies 
are only temporarily effective  (33). Consequently, it is likely that FCR is exacerbated and 
maintained as the psychological distress is not explicitly addressed.  
Significant outcomes were reported for psychological mechanisms, specifically illness 
perceptions (46, 47, 59). Similar findings have been reported in the cancer survivorship, as 
illness perceptions have been associated with higher FCR and worry about cancer more 
generally (11, 82, 84). Furthermore, individual interpretations or representations are often 
more influential than clinical characteristics in determining FCR (66). However, a review of 
psychological distress in cancer survivors reported no consistent evidence that measures of 
illness appraisal predicted longer-term distress (68). Although only a small proportion of the 
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studies included in the review examined psychological mechanisms, the findings provide a 
strong argument for further research to be carried out in this area in order to enhance 
understanding. 
 
4.1 Methodological limitations and implications for research 
The review identified significant findings with regards to associations and predictors 
of FCR in caregivers of cancer survivors. However, there are several limitations which must 
be taken into consideration. As only published data were searched and included in this 
review, there is a possibility that relevant studies were missed. Furthermore, only citations 
written in English were considered for inclusion for review, which may have resulted in a 
language, selection or cultural bias.  
It is also important to consider the methodological limitations of the included studies. 
There is likely to be a risk of self-selection bias as recruitment methods were reliant on 
patients responding to the research adverts. Eight out of the 16 studies used a cross-sectional 
study design, thus precluding the ability to draw causal inferences. However, the nine 
prospective studies included in the review all reported an adequate follow-up period. Most 
studies reported data from the USA and participants were predominantly Caucasian females, 
thus may not reflect a representative sample of the population. It is also important to note that 
cancer patients were in different stages of diagnosis, therefore associations with FCR could 
differ as those caring for patients with more advanced cancer may perceive the diagnosis as 
being more serious and more likely to recur (11). Future research should attempt to address 
the observed limitations by recruiting larger, more representative samples of carers of 
patients with a range of different cancers. 
With regards to the quality of studies, only five studies reported a sample size 
calculation, thus studies are potentially statistically underpowered and at risk of Type I error 
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rates. Researchers should ensure that this is stipulated in future research papers, in order to 
ensure confidence in the statistical power of findings. Only three articles considered the 
psychological mechanisms associated with FCR in family caregivers (46, 47, 59), whilst the 
remaining studies investigated demographic factors and interpersonal processes. Future 
research should consider the psychological processes that underpin FCR in caregivers in 
order to enhance current psychological interventions and support. 
 
4.2 Clinical implications 
A total of 16 studies examined the associations between demographic, clinical and 
psychological factors and caregiver FCR, yet as the studies looked at different aspects, it is 
therefore hard to draw conclusions from the review findings. Nonetheless, significant 
associations were found between FCR and certain demographic and clinical factors, 
including younger age and treatment modality. Health professionals may want to consider 
this when offering information on treatment approaches and providing the space to discuss 
concerns about recurrence. Previous research has identified a need for planning for transition 
from patient to ‘survivor’ (85, 86), which involves discussions around treatment, ongoing 
management, managing FCR and identifying triggers for seeking help and support from 
healthcare team (87). Caregivers should be included in care planning, where possible, in 
order to have the opportunity to raise any concerns about the cancer returning and have a 
clear sense of treatment approaches and ongoing support. In cases where the patient does not 
want the caregiver to be involved in the care plan, caregivers should be offered their own 
support as the cancer experience can result in the caregiver adapting to a “new normal” and 
potentially altered future and sense of self (81).  
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Given the paucity of research investigating psychological mechanisms underpinning 
FCR in caregivers of cancer survivors, further research which assesses psychological factors 
that are predictive of FCR is warranted before suggestions for interventions can be made.  
 
4.3 Conclusions 
The results of the review indicate that caregiver FCR is a significant concern and 
highlights the importance of furthering current understanding of this prevalent issue. Weak to 
moderate associations were found between certain demographic and clinical factors and 
increased FCR. The limited research investigating the psychological mechanisms reported 
that illness perceptions explained additional variance in FCR when controlling for 
demographic and clinical characteristics. Further research examining modifiable factors are 
required, in order to enhance understanding of the psychological mechanisms that are 
involved in the development and maintenance of FCR in caregivers of cancer survivors. By 
investigating modifiable factors, this will provide evidence and guide the development of 
appropriate and effective interventions for this population. 
 
 
 
 
 
 
 
 
 
 
 
27 
 
Figure 1. Flowchart of literature search (based on PRISMA guidelines) (38) 
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Table 1: Measures of demographic, clinical and psychosocial factors 
Correlate or predictor 
variables 
Studies analysing correlate 
or predictor variables 
Studies with 
significant 
results (n) 
Demographic (n = 12 studies 
reported in 13 articles)  
  
  Age sig. (42, 46, 51, 53, 57, 58) n.s. 
(41, 47, 48, 49, 50, 55, 56) 
6 
  Gender sig. (57) n.s. (47, 53, 56) 1 
  Ethnicity sig. (41) n.s. (50, 53) 1 
  Education sig. (50) n.s. (41, 49, 53, 55, 
56, 58) 
1 
    
Clinical (n = 14)   
  Time since diagnosis sig. (49, 57) n.s. (46, 47, 50, 
51, 53, 58) 
2 
  Cancer stage n.s. (41, 49, 51, 53, 55-57) 0 
  Cancer severity sig. (51) 1 
  Comorbidities sig. (41, 49) n.s. (46, 47, 53) 2 
  Survivor physical health sig. (51) 1 
  Treatment type sig. (41, 49, 54, 57) n.s. (53, 
55, 58) 
4 
  Medical follow-up sig. (43, 44) 2 
   
Psychosocial (n = 15 studies 
reported in 18 articles) 
  
  Anxiety sig. (42, 44, 51) 3 
  Emotional distress sig. (56) 1 
  Negative affect sig. (42) 1 
  Survivor/caregiver FCR sig. (42, 44, 45, 48, 49, 51, 53, 
56, 58) n.s. (54, 55) 
8 studies reported 
in 9 articles 
  Relationship quality sig. (42) n.s. (55) 1 
  Social support sig. (49) n.s. (48, 52, 53, 57) 1 
  Loneliness sig. (57) 1 
  Communication sig. (42, 43, 45, 50, 59) 4 studies reported 
in 5 articles 
  Stress sig. (48, 52, 53, 57) 2 studies reported 
in 4 articles 
  Coping strategies sig. (46, 47) 2 
  Quality of life sig. (48, 51, 52, 57, 58) 4 studies reported 
in 5 articles 
  Meaning of illness sig. (48, 52, 53) 1 study reported 
in 3 articles 
  Illness perceptions sig. (46, 47, 59) 3 
 
Note. sig = significant results; n.s. = Non-significant results;  
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Table 2: Study characteristics 
   Caregiver Survivor 
Author, 
(year), 
country 
Design n Age (years) 
(SD) 
Gender, 
n (%) 
Relationship to 
survivor, n (%) 
 
Cancer type Stage, 
n (%) 
Time since diagnosis 
(SD) 
Treatment, 
n (%) 
Boehmer et 
al. (2016), 
USA 
 
Cross-
sectional 
H* 43 
 
 
 
 
 
 
M† 124 
M = 62.4 (8.0) 
 
 
 
 
 
 
M = 55.8 (9.3) 
 
Female: 7 
(16.3) 
Male: 36 
(83.7) 
 
 
 
Female: 116 
(93.5) 
Male: 8 (6.5) 
 
Partner: 36 
(83.7) 
Child: 3 (7.0) 
Sibling: 2 (4.7) 
Parent: 1 (2.3) 
Friend: 1 (2.3) 
 
Partner: 106 
(85.5) 
Child: 0 (0.0) 
Sibling: 3 (2.4) 
Parent: 3 (2.4) 
Friend: 12 (9.7) 
Breast 
 
 
 
 
 
 
Breast 
I: 18 (42.9) 
II: 12 (28.6) 
III: 4 (9.5) 
 
 
 
 
I: 46 (37.1) 
II: 40 (32.3) 
III: 12 (9.7) 
5.8 years (3.9) 
 
 
 
 
 
 
7.3 years (3.6) 
L: 41 (95.3) 
M: 0 (0.0) 
M + (Re): 2 
(4.7) 
R: 32 (74.4)  
H: 31 (72.1) 
 
L: 105 (84.7) 
M: 10 (8.1) 
M + (Re): 9 
(7.3) 
R: 80 (64.5) 
H: 88 (71.0) 
 
Chien et al. 
(2018), 
Taiwan 
Longitudinal 
(T4 = 24 
weeks) 
T4 =46 M = 62.0 (7.8) Female: 48 
(100.0) 
Male: 0 (0.0) 
 
Partner: 48 
(100.0) 
Prostate II: 30 (62.5) 
III: 
18(37.5) 
Recruited when first 
diagnosed 
S: 37 (77.1) 
R: 11 (22.9)  
Cohee et al. 
(2017), 
USA 
 
Cross-
sectional 
222 M = 47.98 (7.2) Not reported Partner: 222 
(100.0) 
Breast Not 
reported 
5.83 years (1.51) Not reported 
Dempster 
et al. 
(2011), UK 
Cross-
sectional 
382 M = 62 (10.91) Female: 257 
(67) 
Male: 125 (33) 
Partner: 359 
(94.0) 
Other family: 23 
(6.0) 
Oesophageal Not 
reported 
Mdn = 46 months (19–
81) 
Not reported 
 
* Cancer survivors who identify as heterosexual women (HSW) 
† Cancer survivors who identify as sexual minority women (SMW) 
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   Caregiver Survivor 
Author, 
(year), 
country 
Design n Age (years) 
(SD) 
Gender, 
n (%) 
Relationship to 
survivor, n (%) 
 
Cancer type Stage, 
n (%) 
Time since diagnosis 
(SD) 
Treatment, 
n (%) 
Graham et 
al. (2016), 
UK 
Longitudinal 
(T2 = 12 
months) 
171 M = 62.56 
(10.05) 
Female: 
124 (72.5) 
Male: 47 
(27.5) 
 
Partner: 
165(96.49) 
Other: 6 (3.51) 
 
Oesophageal Not 
reported 
M = 4 years (2–7) 
 
Not reported 
 
Hodges & 
Humphris 
(2009), UK 
Longitudinal 
(T2 = 6 
months) 
101 M = 56.26 (30 – 
76) 
Female: 73 
(72.3) 
Male: 28 
(27.7) 
Partner: 86 
(85.1) 
Non-partner: 15 
(14.9) 
 
Head and 
neck 
1-2 = 27 
(60) 
3-4 = 16 
(35.6) 
5 = 2 (4.4) 
 
Not reported Not reported 
Janz et al. 
(2016), 
USA 
Longitudinal
* 
510 <50 N = 70 
(13.7%) 
50-65 N = 218 
(42.75%) 
>65 N = 222 
(43.5%) 
 
Not reported Partner: 510 
(100.0) 
Breast 0 :125 
(24.5) 
I-II: 388 
(66.3) 
III: 46 (9.0) 
4 years 
 
L: 324 (63.6) 
(U)M:128 
(25.1) 
(B) M:51 
(10.0) 
R: 363 (71.1) 
C: 229 (44.9) 
 
Kim et al. 
(2012), 
USA 
Cross-
sectional 
455 M = 56.19 
(13.01) 
Female: 288 
(63.3) 
Male: 167 
(36.7) 
 
Spouse: 305 
(67.1) 
Offspring: 84 
(18.5) 
Other: 66 (14.4) 
 
Mixed† 
 
Localized: 
292(64.2) 
Regional: 
124(27.3) 
Distant: 39 
(8.6) 
 
2.2 years (0.40) Not reported 
 
 
 
* Partners surveyed at Time 2 only 
† Mixed cohort = breast, prostate, colorectal, lung, ovarian, kidney, uterine, bladder, non-Hodgkin’s lymphoma, skin melanoma 
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   Caregiver Survivor 
Author, 
(year), 
country 
Design n Age (years) 
(SD) 
Gender, 
n (%) 
Relationship to 
survivor, n (%) 
 
Cancer type Stage, 
n (%) 
Time since diagnosis 
(SD) 
Treatment, 
n (%) 
Maguire et 
al. (2017), 
Ireland 
Cross-
sectional 
180 M = 57.3 
(12.48) 
Female: 136 
(76.0)  
Male: 44 
(24.0) 
 
Spouse: 132 
(73.4) 
Offspring or 
parent: 34 (18.8) 
Other:14 (7.8) 
 
Head and 
neck 
I-II: 81 
(54.4) 
III-IV: 68 
(45.6) 
 
4.9 years (3.79)  S: 31 (17.2) 
C: 47 (26.1) 
R: 122 (67.4) 
 
Mellon & 
Northouse 
(2001); 
Mellon et 
al. (2006; 
2007), USA 
Cross-
sectional 
123 M = 55 (14.5) 
(21-80) 
Female: 80 
(65) 
Male:43 (35) 
Spouse: 65 
(52.8) 
Child: 36 (29.3) 
Sibling: 10 (8.1) 
Significant 
other: 12 (9.8) 
 
Mixed* Not 
reported 
3.39 years (1.0)  S: 108 (87.8) 
R: 48 (39.0) 
C: 28 (22.8) 
H: 4 (3) 
 
Perndorfer 
et al. 
(2019), 
USA 
Longitudinal 
(21-day 
diary) 
69 M = 58 (10) Not reported Partner: 69 
(100.0) 
Breast 0: 8 (12) 
IA: 37 (53) 
IIA: 17 (25) 
IIB: 6 (9) 
IIIA: 1 (1) 
 
5 months (2.09) after 
treatment 
C: 21 (30) 
R: 50 (72) 
H: 58 (84) 
 
Soriano et 
al. (2018a), 
USA 
Study (1) 
Cross-
sectional 
 
46 
 
 
M = 54.57 
(13.31) 
 
Not reported 
 
Partner: 46 
(100.0) 
 
 
Breast 0: 11 (24) 
I: 17 (37) 
II: 15 (32) 
IIIa: 3 (7) 
7.70 months after 
treatment 
 
 
 
C and/or H: 15 
(33) 
 
 
Soriano et 
al. (2018a), 
USA 
Study (2) 
Longitudinal 
(21-day 
diary) 
72 M = 59.49 
(10.34) 
Male:70 (97) 
Female: 2 (3) 
 
Partner: 72 
(100.0) 
Breast 0: 10 (14) 
I: 34 (47) 
II: 27 (37) 
IIIa: 17 (23) 
 
5.77 weeks after 
treatment 
C: 24 (33) 
H: 58 (81) 
 
 
* Mixed cohort = Breast, prostate, colon-rectal, uterine 
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   Caregiver Survivor 
Author, 
(year), 
country 
Design n Age (years) 
(SD) 
Gender, 
n (%) 
Relationship to 
survivor, n (%) 
 
Cancer type Stage, 
n (%) 
Time since diagnosis 
(SD) 
Treatment, 
n (%) 
Soriano et 
al. (2018b; 
2019), USA 
Longitudinal 
(21-day 
diary) 
57 M = 60 (10) Male: 55 (96) 
Female: 2 (4) 
 
Partner: 57 
(100.0) 
Breast 0: 7 (12) 
IA: 30 (53) 
IIA: 14 (25) 
IIB: 5 (9) 
IIIA: 1 (1) 
 
12.2 months (1.9)  C:17 (30) 
R: 41 (72) 
H: 48 (84) 
 
van de Wal 
et al. 
(2017), The 
Netherlands 
 
Cross-
sectional 
168 Mdn = 67.4 (40-
86) 
Not reported Partner: 168 
(100.0) 
Prostate Not 
reported 
Mdn = 7.5 years (0.9-
20.0)  
S:126 (75) 
S + R: 41 (25) 
Wu et al. 
(2019), 
USA 
Longitudinal 
(T1 = 6 
months; T2 = 
12 months) 
62 M = 64.3 (8.4) Not reported Partner: 62 
(100.0) 
Prostate Not 
reported 
89.8 days (95.0) R: 36 (52.2) 
S: 18 (26.1) 
B: 7 (10.1) 
R + B: 3 (4.3) 
S + R: 1 (1.4) 
WW: 1 (1.4) 
Missing: 3 
(4.3) 
 
Xu et al. 
(2019), 
China 
 
Longitudinal 
(10 days) 
54 Not reported Not reported Partner: 54 
(100.0) 
Breast I: 22 (40.7) 
II:14 (25.9) 
III:18 
(33.3) 
 
22.1 months (19.88) Not reported 
Note. Treatment modality: S = Surgery; C = Chemotherapy; R = Radiotherapy; L = Lumpectomy; M = Mastectomy; M + Re = Mastectomy and 
Reconstruction; (U)M = Unilateral Mastectomy; (B)M = Bilateral Mastectomy; H = Hormonal therapy; B = Brachytherapy; WW = Watchful waiting 
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Table 3: Assessment of risk of bias 
Author Unbiased 
selection 
of 
cohort? 
Sample size 
calculation
? 
Adequate 
description 
of cohort? 
Validated 
method for 
assessing 
predictor/ 
outcome 
variables? 
Validated 
method for 
assessing fear 
of cancer 
recurrence? 
Adequate 
follow-up 
period? 
Missing 
data 
minimal? 
Confounders 
controlled 
for? 
Appropriate 
analyses? 
Total 
score 
for 
study 
Boehmer et al. (2016) ● 
¡ 
 
 ● ● ● N/a ● ● ● 7 
Chien et al. (2018) ●  ● ● ● ● ● ◐ ● 7.5 
Cohee et al. (2017) ●  ● ● ● N/a ● ● ● 7 
Dempster et al. (2011) ◐  ◐ ● ● N/a ◐ ● ● 5.5 
Graham et al. (2016) ●  ◐ ● ● ●  ● ● 6.5 
Hodges & Humphris 
(2009) 
● ● ● ● ● ● ● ● ● 9 
Janz et al. (2016) ●  ● ● ◐ N/a ● ● ● 6.5 
Kim et al. (2012) ● ● ● ● ◐ N/a ● ● ● 7.5 
Maguire et al. (2017) ● ● ● ● ● N/a ● ● ● 8 
Mellon & Northouse 
(2001) 
●  ● ● ● N/a ● ● ● 7 
Mellon et al. (2006) ● ● ● ● ● N/a ● ● ● 8 
Mellon et al. (2007) ●  ● ● ● N/a ● ● ● 7 
Perndorfer et al. 
(2019) 
●  ● ● ● ● 
 
● ● ● 8 
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Author Unbiased 
selection 
of 
cohort? 
Sample size 
calculation
? 
Adequate 
description 
of cohort? 
Validated 
method for 
assessing 
predictor/ 
outcome 
variables? 
Validated 
method for 
assessing fear 
of cancer 
recurrence? 
Adequate 
follow-up 
period? 
Missing 
data 
minimal? 
Confounders 
controlled 
for? 
Appropriate 
analyses? 
Total 
score 
for 
study 
Soriano et al. (2018a) 
Study (1) 
●  ● ● ● N/a ● ● ● 7 
Soriano et al. (2018a) 
Study (2) 
●  ● ● ● ● ● ● ● 8 
Soriano et al. (2018b) ●  ● ◐ ● ● ● ● ● 7.5 
Soriano et al. (2019) ●  ● ● ● ● ●  ● 7 
van de Wal et al. 
(2017) 
● ● ● ● ● N/a ● ● ● 8 
Wu et al. (2019) ●  ● ● ◐ ● ● ● ● 7.5 
Xu et al. (2019) ●   ● ◐ ● ◐ ● ● 6 
Total score for each 
area 
19.5 5 18 19.5 18 9 18 18.5 20  
Note. ● = Yes; ◐ = Unclear, Partially; = No; N/a = Not applicable. 
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Table 4: Main study findings 
 Dependent 
variable 
 Independent variables Significant findings 
Author, 
(year) 
FCR score 
(SD) 
Analysis Non-psychosocial 
(demographic, clinical) 
Psychosocial 
 
 
 
Boehmer et 
al. (2016) 
 
FRQ* 
HSW†: 75.2 
(13.6) 
SMW‡: 71.8 
(16.5) 
 
Multivariate 
logistic 
regression 
 
 
 
 
 
Sexual orientation; Co-
residence; Years since 
diagnosis; Treatment type; 
Survivor comorbidities; 
Chemotherapy; Co-
residence 
 
Caregiver use of counselling in 
relation to cancer diagnosis; 
Social support (Survivor, 
Caregiver); Experience of 
discrimination (Caregiver); FCR 
score (Survivor) 
Non-psychosocial 
Years since diagnosis (β = -0.25***); Anti-
oestrogen therapy (β = 0.22***); Survivor 
comorbidities (β = 0.25***) 
 
Psychosocial 
Caregiver and Survivor FCR: r2 = .29*** 
Social support (Caregiver) (β = -0.24***) 
 
Chien et al. 
(2018) 
MAX-PC§ 
5.22 (1.78) 
 
Multivariate 
logistic 
regression 
Age (Patient); Religion 
(Patient, Partner); 
Employment status 
(Patient, Partner); 
Education level (Patient, 
Partner); Self-perceived 
health status (Patient); 
Treatment type 
(radiotherapy); Cancer 
stage; Living arrangement 
(Partner) 
 
FCR score (Patient); Relationship 
satisfaction (Patient, Partner) 
Non-psychosocial 
None. 
 
Psychosocial 
None. 
 
 
Cohee et al. 
(2017) 
CARS** 
11.794 (4-24) 
Correlation; 
Mediation 
Age (Survivors, Partners); 
Ethnicity; Education; 
Social constraints; Cognitive 
processing 
Non-psychosocial 
Education r = -.164* 
 
* FRQ = Fear of Cancer Recurrence Questionnaire (88). Higher scores indicate greater level of FCR (score range 22 – 110). 
†Caregivers of cancer survivors who identify as heterosexual women (HSW) 
‡ Caregivers of cancer survivors who identify as sexual minority women (SMW) 
§ MAX-PC = Memorial Anxiety Scale for Prostate Cancer (89). Scale consists of 18 items, four-point Likert scale. Higher scores indicative of higher anxiety. 
** CARS = Concerns About Recurrence Scale (90). Four items, ranging from 0-5. Higher scores indicative of greater FCR.  
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 Dependent 
variable 
 Independent variables Significant findings 
Author, 
(year) 
FCR score 
(SD) 
Analysis Non-psychosocial 
(demographic, clinical) 
Psychosocial 
 
 
 
Religion; Comorbidities; 
Time since diagnosis  
 
Psychosocial 
X (social constraints); M (cognitive 
processing) 
Indirect effect = 0.184, 95% bootstrap CI = 
0.119 to 0.271. 
Direct effect = 0.038, p = 0.469, 95% CI = -
0.066 to -.142. 
[F(3,215 = 27.917, R2 = 0.280, p < .001] 
 
Dempster 
et al. 
(2011) 
CARS 
13.93 (5.83) 
Correlations; 
Regression 
Age; Gender; 
Relationship to survivor; 
Months since diagnosis; 
Comorbidities 
Anxiety; Depression; Illness 
perceptions: Acute/chronic 
timeline; Cyclical timeline; 
Treatment control; Emotional 
cause; Behavioural cause; 
Externalised cause; Consequences 
(Patient, Carer); Personal control 
(Patient, Carer); Illness coherence 
(Patient, Carer) 
Coping strategies 
(Reflection/relaxation, Positive 
focus, Diversion, Planning, 
Interpersonal) 
Non-psychosocial 
Age (β = -0.171***) 
 
Psychosocial 
Cyclical timeline: r = .275***; 
Consequences (Patient): r = .306***; 
Consequences (Carer): r = .475*** 
Reflection/relaxation: r = .333***; 
Diversion: r = .327***; Interpersonal: r = 
.354*** 
Illness coherence (Carer) (β = -0.093*); 
Consequences (Carer) (β = 0.273***); 
Externalised cause (β = -0.124**) 
Reflection/relaxation (β = 0.165**); 
Positive focus (β = -0.107*); Interpersonal 
(β = 0.179**) 
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 Dependent 
variable 
 Independent variables Significant findings 
Author, 
(year) 
FCR score 
(SD) 
Analysis Non-psychosocial 
(demographic, clinical) 
Psychosocial 
 
 
 
Graham et 
al. (2016) 
CARS 
T1:13.65 (5.58) 
T2: 13.97 (5.59) 
 
Hierarchical 
regression 
Age; Gender; 
Relationship to survivor; 
Living arrangement; 
Months since diagnosis; 
Other illness/medical 
condition 
Anxiety; Depression; IPQR-
Cluster 2 versus 1*; IPQR-Cluster 
3 versus1; Coping strategies 
(Planning, Interpersonal, 
Relaxation, Positive focus) 
Non-psychosocial 
None. 
 
Psychosocial 
IPQR-Cluster 3 versus 1 (β = -0.205*); 
Interpersonal (β = 0.218*) 
 
Hodges & 
Humphris 
(2009) 
WOC† 
T1: 11.77 (4.98) 
T2: 11.71 (5.21) 
 
Correlations; 
Path analysis 
Age (Patient, Carer); 
Gender (Patient, Carer); 
Relation to patient; Co-
habiting status; Children; 
Employment status; 
Cancer site; Cancer stage 
Anxiety; Depression; FCR score 
(Patient) 
Non-psychosocial 
None. 
 
Psychosocial 
Carer FCR (3 and 6 months) r = .754***; 
Patient and carer FCR (6 months) r = 
.375** 
Carer distress: r = .734**; (β = 0.20**); 
Patient FCR (3 months) (β = 0.18**); Carer 
FCR (3 months) (β = 0.69*) 
 
Janz et al. 
(2016) 
Worry scale ‡ 
N = 212 
(47.1%) 
Logistic 
regression 
Age; Ethnicity; Education 
level; Health status; 
Comorbidities; Cancer 
Received enough information on 
risk of recurrence from health care 
Non-psychosocial 
 
* IPQ Clusters: Cluster 1 = Carers have increasingly strong causal beliefs, particularly beliefs in emotional cause; Cluster 2 = Carers increasingly believe that they and the 
survivor understand condition, and feel over time that there will be less severe consequences for themselves and the survivor; Cluster 3 = Carers report decreasing belief in 
severe consequences for survivor and carer, increase in perception that condition is acute and increase in all control beliefs. 
† WOC = Worry Of Cancer scale (91). Total composite score from two items used ranged from 0-20. 
‡ Adapted worry scale used in previous publications (92, 93). Scores M = ≥ 3 considered “worriers”.  
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 Dependent 
variable 
 Independent variables Significant findings 
Author, 
(year) 
FCR score 
(SD) 
Analysis Non-psychosocial 
(demographic, clinical) 
Psychosocial 
 
 
 
 stage; Treatment type 
(Chemotherapy, 
Radiation, Surgery) 
providers; Emotional support 
from health care providers; 
Non-Hispanic Black (β = .053**); Latino 
(higher acculturation) (β = 3.05**); Latino 
(lower acculturation) (β = 2.96**); 
One or more comorbidities (β = 1.95*); 
Chemotherapy (β = 2.77**) 
 
Psychosocial 
None. 
 
Kim et al. 
(2012) 
Adapted item* 
 -0.04 (0.99) 
Correlations; 
Modelling 
analysis 
Age (Survivor, 
Caregiver); Cancer 
severity 
Anxiety; Quality of life (QoL): 
mental health and physical health 
(Survivor, Caregiver); FCR score 
(Survivor) 
Non-psychosocial 
Age: r = -.174***; Cancer severity (β = 
0.197***) 
 
Psychosocial 
QoL Mental health (Caregiver): r = -
.296***; Anxiety: r = .239***; Survivor 
and Caregiver FCR: r = .19***; QoL 
Physical health (Survivor): (β -0.127**); 
Mental health (Caregiver): (β = -0.147***) 
 
Maguire et 
al. (2017) 
WOC 
9.6 (5.82) 
Correlations; 
Multiple 
regression 
Age (Survivor, 
Caregiver); Gender 
(Caregiver); Time since 
diagnosis; Cancer stage; 
Treatment type (Surgery, 
Financial stress of caring; Time 
caring; Social support; 
Loneliness; QoL (Survivor) 
Non-psychosocial 
Time since diagnosis: r = -.18*; 
Chemotherapy: r = .14*; Extent of surgery: 
r = -.25*** 
 
* Adapted from (94) measure. Higher score reflects greater FCR, zero score reflects moderate levels of FCR. 
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 Dependent 
variable 
 Independent variables Significant findings 
Author, 
(year) 
FCR score 
(SD) 
Analysis Non-psychosocial 
(demographic, clinical) 
Psychosocial 
 
 
 
Chemotherapy, 
Radiotherapy); 
Relationship to survivor; 
Employment status 
Age (Survivor) (b = -0.22*); Age 
(Caregiver) (b = 0.22*); Caregiver gender: 
(r = .21*); (b = 0.25***); Extent of surgery 
(b = -0.23***) 
 
Psychosocial 
Survivor QoL: r = -.28***; Time caring: r 
= .34***; Loneliness: r = .27*** 
Financial stress of caring: (b = 0.20*); 
Time caring: (b = 0.37***); Loneliness: (b 
= 0.25***) 
 
Mellon et 
al. (2006) 
FRQ 
73.1 (14.1) 
Correlations None. 
 
Family stressors; Family 
hardiness; Social support; Family 
meaning of illness; Family QoL; 
Somatic concerns (Patient) 
Non-psychosocial 
None. 
 
Psychosocial 
Family stressors: r = .29*; Meaning of 
illness: r = -.28**; QoL: r = -.29* 
 
Mellon et 
al. (2007) 
FRQ 
NR 
Correlations; 
Modelling 
analysis 
Age (Survivor, 
Caregiver); Gender 
(Survivor, Caregiver); 
Ethnicity (Survivor, 
Caregiver); Education 
level (Survivor, 
Caregiver); Role of 
relationship to survivor; 
Concurrent family stressors 
(Actor effect, Partner effect); 
Family hardiness; Social support; 
Family meaning of cancer illness 
(Actor effect, Partner effect); 
Somatic concerns; FCR score 
(survivor) 
Non-psychosocial 
Age (Partner effect): (β = -0.52*) 
 
Psychosocial 
Concurrent family stressors: r = .29**; 
Meaning of cancer illness: r = -.28**; 
Survivor FCR: r = .41*** 
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 Dependent 
variable 
 Independent variables Significant findings 
Author, 
(year) 
FCR score 
(SD) 
Analysis Non-psychosocial 
(demographic, clinical) 
Psychosocial 
 
 
 
Time since diagnosis; 
Other health problems 
Concurrent family stressors (Actor effect): 
(β = 0.34***); Family meaning of cancer 
illness (Actor effect): (β = -1.24**); 
Survivor vs. family caregiver: (β = -
4.89***) 
 
Mellon & 
Northouse 
(2001) 
FRQ 
NR  
Correlations None. Family QoL; Family stressors; 
Family hardiness; Family social 
support; Family meaning of 
illness; Somatic concerns; FCR 
score (Patient) 
Non-psychosocial 
None. 
 
Psychosocial 
Family QoL: r = -.33***; Family stressors: 
r = .24**; Patient FCR: r = .40***; Family 
meaning of illness: r = -.27** 
 
Perndorfer 
et al. 
(2019) 
FCRI* 
Spouse evening 
FCR:1.43 
Correlations None. Daily protective buffering 
(Patient, Spouse); Intimacy; 
Evening FCR score (Patient, 
Partner) 
Non-psychosocial 
None. 
 
Psychosocial 
Protective buffering (Patient): r = .15***; 
Protective buffering (Spouse): r = .25***; 
Evening intimacy (Patient): r = -.12***; 
Evening FCR score (Patient): r = .21*** 
 
 
* FCRI = Fear of Cancer Recurrence Inventory (35). Six items ranging from 0-4. Higher scores indicative of greater FCR. 
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 Dependent 
variable 
 Independent variables Significant findings 
Author, 
(year) 
FCR score 
(SD) 
Analysis Non-psychosocial 
(demographic, clinical) 
Psychosocial 
 
 
 
Soriano et 
al. (2018a) 
Study (1) 
Global FCR: 
CARS = 3.18 
 
 
 
 
 
Correlations; 
Modelling 
analysis 
Age (Patient); Patient 
physical symptoms 
Social Constraints (Patient, 
Spouse); Anxiety; Depression; 
Relationship quality (Patient, 
Spouse) 
Non-psychosocial 
Age (Patient) (β = -0.028*) 
 
Psychosocial 
FCR (Patient and Spouse): r = .53***; 
Anxiety r = .31*; Social constraints 
(Spouse): (β = 0.561*); Relationship 
quality (Spouse): (β = 0.050*)  
 
Soriano et 
al. (2018a) 
Study (2) 
FCRI = 1.51 Correlations; 
Modelling 
analysis 
None. Social Constraints (Patient, 
Spouse); Negative affect (Patient, 
Spouse); Relationship quality 
(Patient, Spouse); FCR score 
(Spouse same day) 
Non-psychosocial 
None. 
 
Psychosocial 
FCR score (Patient and Spouse): r = 
.22***; Social constraints: r = .27**; 
Negative affect: r = .32** 
(DV: Same day FCR): 
Social constraints (Spouse): (β = 
0.978***)*; Social constraints (Patient): (β 
= 1.088*); Negative affect (Spouse): (β = 
0.496**) 
(DV: Next day FCR): 
Negative affect (Spouse): (β = 0.255**); 
Relationship quality (Spouse): (β = 0.091*) 
 
* Random effects greater but still significant 
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 Dependent 
variable 
 Independent variables Significant findings 
Author, 
(year) 
FCR score 
(SD) 
Analysis Non-psychosocial 
(demographic, clinical) 
Psychosocial 
 
 
 
 
Soriano et 
al. (2018b) 
FCRI 
Baseline* = 5 
(4). 
T1 = 1.117 
(1.754) 
T2 = 0.840 
(1.296) 
T3 = 0.570 
(1.483) 
 
Modelling 
analysis 
None. Capitalization attempt (Spouse, 
Patient); Perceived partner 
responsiveness (Spouse); Event 
positivity 
Non-psychosocial 
None. 
 
Psychosocial 
T3: Capitalization attempt (Spouse)† (β = 
0.488**); Patient capitalization attempt 
(Patient)23 (β = -0.662**); Perceived 
partner responsiveness‡ (β = -0.421**) 
 
Soriano et 
al. (2019) 
FCRI 
0.96 (1.78) 
Correlations; 
Modelling 
analysis 
None. Threat sensitivity (Patient, 
Spouse); Anxiety (Patient, 
Spouse); FCR score (Patient) 
Non-psychosocial 
None. 
 
Psychosocial 
Patient FCR: r = .29*; Anxiety (Spouse): r = 
.39*; 
Threat sensitivity (Spouse): (β = 0.408**) 
 
van de Wal 
et al. 
(2017) 
CWS§ 
12.6 (3.5) 
Regression; 
Mean 
comparison 
Age (Partner); Years a 
couple; Cancer history 
(Partner); Education level 
(Partner); Children; Time 
FCR score (Survivor); Health-
related QoL (physical, social, 
physical role and emotional role 
Non-psychosocial 
Age: (β = -0.295*) 
 
Psychosocial 
 
* One week prior to diary period 
† N = 56 couples 
‡ N = 53 couples 
§ CWS = Cancer Worry Scale, stipulating a cut-off score for high FCR as ≥14 
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 Dependent 
variable 
 Independent variables Significant findings 
Author, 
(year) 
FCR score 
(SD) 
Analysis Non-psychosocial 
(demographic, clinical) 
Psychosocial 
 
 
 
since diagnosis; Type of 
treatment 
functioning; mental health; 
vitality; pain; general health) 
Survivor FCR score: (r = .44***); (β = 
0.304***) 
High partner FCR vs low partner FCR: 
Emotional role functioning (p = .023*); 
Mental health (p < .001***); Vitality (p = 
.038*); General health (p = .042*) 
 
Wu et al. 
(2019) 
Cancer specific 
worry measure* 
NR 
Modelling 
analysis 
Type of treatment 
(Radiation, Surgery) 
FCR scores at baseline and six-
months (Patient, Spouse) 
Non-psychosocial 
Six-month time point: Surgery (β = -
0.25**) 
 
Psychosocial 
Six-month time point: Baseline FCR 
(Spouse) (β = 0.62***) 
Twelve-month time point: Six-month FCR 
(Spouse) (β = 0.73***) 
 
Xu et al. 
(2019) 
Adapted 
measure† 
19.82 (17.77) 
Modelling 
analysis; 
Mediation 
analysis 
None. Illness representation; Daily 
Couple Communication 
(perceptions of positive and 
negative information) 
Non-psychosocial 
None. 
 
Psychosocial 
Spouses’ perception of positive 
information: (β = -0.168***); Spouses’ 
 
*(95). Mean of two responses calculated, higher scores indicated greater FCR. 
† Five items adapted from prior research (96), rated on a seven-point Likert scale.  
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 Dependent 
variable 
 Independent variables Significant findings 
Author, 
(year) 
FCR score 
(SD) 
Analysis Non-psychosocial 
(demographic, clinical) 
Psychosocial 
 
 
 
perceptions of negative information: (β = 
1.045***) 
Note. Methods: Multivariate regression models analysis (regression, mixed models and generalised linear); Modelling analysis (path analysis, structure equation 
modelling and actor-partner interdependence model). NR = Not Reported. 
*** p < .001; ** p < .01; * p < .05 
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Abstract 
Objective: Partners of cancer survivors often report anxiety, depression and fear that their 
partners cancer will return, however, the psychological processes underpinning these are not 
well understood. The Self-Regulatory Executive Function (S-REF) model, a transdiagnostic 
model of emotional distress, states that maladaptive metacognitive beliefs (beliefs about 
thoughts) are fundamental to understanding the development and maintenance of emotional 
distress. This study explored whether metacognitive beliefs were associated with fear of cancer 
recurrence (FCR), anxiety and depression in adult partners of adult cancer survivors, after 
accounting for demographic variables and cancer stage. Methods: Eighty-eight participants 
completed a cross-sectional survey measuring demographic and clinical factors, anxiety, 
depression, FCR and metacognitive beliefs. Hierarchical regression modelling was used to 
examine model fit. Results: Regression analyses showed that metacognitive beliefs were 
associated with anxiety, depression and FCR and explained additional variance in anxiety, 
depression and FCR after controlling for age, gender, education and cancer stage. Negative 
metacognitive beliefs were most strongly associated with anxiety, depression and FCR in 
partners of cancer survivors. Conclusions: This is the first study to examine the fit of the S-
REF model to understanding anxiety, depression and FCR experienced by adult partners of 
cancer survivors. Prospective research is necessary to test whether metacognitive beliefs have 
a causal role in anxiety, depression and FCR in this population. Intervention studies are also 
required in order to assess the potential efficacy of targeting and modifying negative 
metacognitive beliefs against traditional cognitive behavioural approaches.    
 
 
 
Keywords: Anxiety, cancer survivors, depression, fear, metacognition, partners, recurrence 
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1. Background 
Cancer diagnosis and treatment can be a challenging experience for survivors, as the 
physical and psychological impact can last well beyond completion of treatment and into the 
survivorship phase (1, 2). Caregivers of cancer survivors, particularly partners who are often 
the survivors’ primary support (3), also experience adverse effects as a result of the cancer 
journey. Anxiety and depression are experienced by approximately 25-56% and 18-35% of 
caregivers respectively (4), with levels often exceeding those of cancer patients (5, 6) and 
community norms (7-9). A commonly reported concern is the “fear, worry, or concern about 
cancer returning or progressing” (10), which can be greater in caregivers than survivors (11-
14) and remain stable even after treatment has been completed (12, 14).  Fear of cancer 
recurrence (FCR) in caregivers is often associated with poorer quality of life (QoL) (15-17), 
loneliness (18), increased stress (15, 19) and heightened emotional distress (17, 20, 21).  
Variables associated with caregiver FCR include younger age (11, 16, 17, 19, 22), cancer 
severity (17), treatment type  (11, 12, 18, 19) and time since diagnosis (18, 19). Similar 
variables have been found to predict partners’ anxiety and depression, including partner 
demographic factors (e.g., younger and female) and clinical factors, such as patients’ cancer 
stage (23). Given the prevalence of adverse psychological effects experienced by partners, it 
is imperative to understand the psychological mechanisms underpinning anxiety, depression 
and FCR.  
A variety of conceptual frameworks have been proposed to account for anxiety, 
depression and FCR in cancer patients and survivors, yet their applicability to caregivers is 
currently unknown. The Common-Sense Model (CSM, 24) is one of the more commonly 
cited frameworks and has received the most empirical support (25, 26). This model states that 
individuals create cognitive and emotional interpretations of an illness threat based on 
information sources currently available to them in order to make sense of, and respond to, 
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said threat (24, 27). However, this model does not fully account for variance in anxiety, 
depression and FCR in caregivers of cancer survivors, as illness perception have only been 
found to account for 21.5% - 33% of variance in these outcomes (22). 
An alternative approach to understanding  anxiety, depression and FCR in cancer 
patients and survivors may be the Self-Regulatory Executive Function (S-REF) model (28), a 
transdiagnostic model of emotional distress. In contrast to traditional cognitive theories that 
state that emotional distress is the consequence of dysfunctional beliefs, the S-REF model 
argues that distress is maintained due to beliefs about thoughts (metacognitive beliefs) and 
how a person responds to such beliefs. Maladaptive metacognitive beliefs activate certain 
patterns of thinking, known as the Cognitive Attentional Syndrome (CAS), which is 
characterised by three processes: i) perseverative thinking (e.g. worry, rumination); ii) 
attentional bias towards sources of threat (e.g., monitoring for negative thoughts and feelings) 
and; iii) ineffective coping strategies (e.g., avoidance, suppression and minimisation). 
 Positive and negative metacognitive beliefs are theorised to be the most influential in 
activating the CAS. Positive beliefs about the usefulness of, and need to engage, in worry 
(e.g., “worrying helps me to solve problems”) reinforces worry and other aspects of the CAS 
as a coping strategy (e.g., avoiding reminders of cancer). However, such strategies are 
counterproductive and maintain a sense of threat which indirectly maintains emotional 
distress. Negative beliefs about the danger and uncontrollability of worry (e.g., “I cannot 
ignore my worrying thoughts”) are hypothesised to maintain and exacerbate the use of the 
CAS as a coping strategy. Negative beliefs result in decreased efforts to stop worry as the 
person believes it is not possible to do so, and therefore act both directly and indirectly to 
maintain emotional distress. 
Given the prevalence of anxiety, depression and FCR in partners of cancer survivors, 
the use of a transdiagnostic model may offer a more cost-effective and time-efficient 
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treatment approach, as multiple psychological difficulties can be treated simultaneously. 
Metacognitive beliefs are positively associated with emotional distress in various physical 
health populations, including chronic pain (29), chronic fatigue syndrome (30), diabetes (31), 
multiple sclerosis (32) and Parkinson’s disease (33). Metacognitive beliefs are also 
significantly associated with anxiety, depression and trauma in cancer patients, with negative 
metacognitive beliefs demonstrating the strongest association with each outcome (34, 35). 
Furthermore, metacognitive therapy, an intervention based on the transdiagnostic model, 
leads to clinically-significant reductions in anxiety, depression, FCR and metacognitive 
beliefs which was maintained at 6-months follow-up (36).  
Consequently, there is substantial support for the utility of the S-REF model in 
understanding anxiety, depression and FCR in cancer patients and survivors, however, no 
research has investigated the application of this model to understanding distress experienced 
by partners of cancer survivors. This study aimed to test the predictions of the S-REF model 
in partner of cancer survivors, whilst controlling for demographic and clinical variables, in 
order to investigate whether this model explains the maintenance of anxiety, depression and 
FCR in partners. It was hypothesised that: 
 (a) metacognitive beliefs will be positively associated with FCR, anxiety and depression 
in partners of cancer survivors;  
 (b) metacognitive beliefs will explain additional variance in FCR, anxiety and 
depression when controlling for demographic and clinical variables. 
 
2. Method 
2.1  Participants 
Adult partners of adults (both aged ≥ 18 years of age) in the survivorship phase of 
cancer who were able to understand English were invited to participate. ‘Survivorship’ was 
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defined as: i) cancer diagnosis at least 6 months ago; ii) completion of acute medical 
treatment for cancer; iii) no diagnosed secondary cancer(s). Participants were not required to 
have been in a relationship with the survivor at the point of the survivor’s diagnosis. All 
participants provided written and informed consent (Appendices E - F). The study was 
approved by the University of Liverpool Research Ethics Committee (Reference 3850; 
Appendix G). 
 
2.2 Procedure 
Participants were recruited to this cross-sectional study via (i) specialist local and 
national cancer charity websites; (ii) cancer charity Facebook and Twitter feeds and; (iii) 
local cancer patient/survivor/family support groups (Appendix H). Participants (n = 106) 
completed an anonymous survey measuring FCR, anxiety, depression and metacognitive 
beliefs, however, approximately 15 % of the sample had to be excluded as participants were 
partners of those diagnosed with advanced or recurrent cancer and metastasis, which did not 
meet the inclusion criteria. Consequently, 88 participants were included in the final sample, 
having completed the survey either online (via Qualtrics; n = 87) or on paper (n = 1), which 
took approximately 20-30 minutes. On completion of the survey, participants were provided 
with a debrief sheet (Appendix I). Participants were asked to indicate if they wished to be 
made aware of research findings by returning their contact details separately. Contact details 
were stored separately from survey responses, in a password-protected file, to ensure that 
specific responses could not be linked back to the participant. Participants were eligible to 
enter a prize draw to win one of six £25 retail vouchers upon completion of the measures. 
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2.3 Measures 
2.3.1 Dependent variables 
The 22-item Fear of Recurrence Questionnaire (FRQ) (37) was used to assess FCR 
(Appendix J). The scale is suitable for use with cancer patients and their partners and consists 
of items that assess extent of health worry, FCR triggers and concerns of significant others. 
Items are scored on a five-point Likert scale with anchor points of 1 (Strongly Agree) and 5 
(Strongly Disagree). Responses are summed to provide a total score ranging from 22-110; 
higher scores indicate greater FCR. Internal consistency of the FRQ in this sample was good 
(α = .89).  
The Hospital and Anxiety and Depression Scale (HADS) (38) was used to assess 
anxiety and depression (Appendix K). The HADS consists of fourteen questions assessing the 
presence of symptoms of anxiety (n = 7) and depression (n = 7) in the preceding week 
(Appendix K). Items are scored on a four-point scale, with options ranging from 0-3.  Scores 
can be summed to produce a total scale score (ranging from 0-42) or subscale anxiety and 
depression scores (each ranging from 0-21), with higher scores reflecting higher levels of 
distress. A cut-off score of 11 or more for each subscale indicates clinically-significant level 
of anxiety or depression (38). The HADS total had good levels of internal consistency in this 
study (α = .92). 
 
2.3.2 Independent variables 
Demographic and clinical information was collected via a self-report questionnaire 
devised for this study (see Appendix L).  Information included participant and survivor age, 
gender, education and employment status, relationship length, number of children, previous 
and current mental health treatment and experience of others known to the participant having 
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had cancer. Participants were also asked to provide information about the cancer survivors’ 
diagnosis (cancer type, stage and treatment history). 
The 30-item Metacognitions Questionnaire-30 (MCQ-30) (39) was used to assess 
metacognitive beliefs (Appendix M). The scale assesses five metacognitive belief domains: 
(1) positive beliefs about worry (e.g., “worrying will help me cope”); (2) negative beliefs 
about the uncontrollability and dangerousness of worry (e.g., “I can’t stop worrying about 
cancer recurrence”); (3) cognitive confidence (e.g., “I don’t trust my memory”); (4) beliefs 
about the need to control thoughts (e.g., “it’s bad to have thoughts about cancer”) and; (5) 
cognitive self-consciousness (e.g., “I monitor my mind for negative thoughts about cancer”). 
Items are rated on a 4-point scale (1= “definitely disagree” to 4 = “definitely agree”).  Total 
subscale scores range from 6-24, with higher scores indicating greater levels of maladaptive 
metacognitive beliefs. Each subscale had good levels of internal consistency in this sample 
(ranging from α = .73 to α = .89).  
The Cognitive Attentional Syndrome Scale (CAS-1) (40) is a 10-item measure, which 
assesses key aspects of the CAS, including worry and rumination, threat monitoring and 
maladaptive coping responses (Appendix N).  Only items 1 – 6 were included in this study, 
as items 7 -10 duplicate the assessment of metacognitive beliefs. The CAS-1 had good levels 
of internal consistency in this study (α = .87). 
 
2.4 Analysis 
Data were analysed using SPSS version 25 (Appendix O). Data were screened for 
normality of distribution which indicated evidence of skewness and kurtosis, therefore 
nonparametric statistics and bootstrapping techniques were used. Intercorrelations between 
predictor variables were tested with non-parametric (Spearman’s Rho) statistics. Mann-
Whitney tests were used to test for differences by gender, previous and current mental health 
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treatment and experience of others known to the participant having had cancer. Kruskal-
Wallis tests were used to test for differences by education, employment status, cancer type, 
stage and treatment. Bonferroni corrections were used to adjust for multiple comparisons.  
Three hierarchical regression analyses were used to test whether metacognitive beliefs 
explained additional variance in FCR, anxiety and depression respectively, in partners of 
cancer survivors, after controlling for demographic and clinical variables. The order of 
variables in the regression model was based on methodological and theoretical significance. 
Step 1 controlled for demographic variables (gender, education, cancer survivor’s age), 
whilst step 2 controlled for cancer stage. The final step tested the prediction that 
metacognitive beliefs (MCQ-30 subscales) would contribute to FCR, anxiety and depression 
after controlling for demographic and clinical variables.   
 
2.4.1 Power calculation 
In order to determine sample size estimation, a priori power analysis was calculated. With 
an alpha (α) = .05 and power = .80, the projected sample size needed with this effect size 
(GPower 3.1) was approximately N = 135 for regression analysis.   
  
3 Results 
3.1 Sample characteristics 
Table 1 outlines the sample characteristics. Of the participants who completed the 
survey, 68.2% were female with a mean age of 53.35 years (SD = 10.24). The average FCR 
score was 88.18 (SD = 10.86). A total of 27.3% of the sample scored above the clinical cut 
off for depression, whilst 52.3% scored above clinical cut off for anxiety. Only 2.3% of the 
sample reported using alcohol to cope with thoughts and feelings all of the time, whilst 
68.2% reported that they never used maladaptive coping strategies. Approximately 15% 
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reported that they spent 50% of the time in the past week focusing attention on things that 
they find threatening (e.g., symptoms, thoughts).  
 
Table 1. Sample characteristics 
     
Demographic N (%)  Clinical N (%) 
Partner   Cancer diagnosis  
  Female 60 (68.2)    Bowel 17 (19.3) 
  Male 28 (31.8)    Prostate 12 (13.6) 
     Head and neck 11 (12.5) 
Education     Testicular 10 (11.4) 
  No qualifications 3 (3.4)    Brain 9 (10.2) 
  School level 39 (44.3)    Breast 9 (6.8) 
  Undergraduate 17 (19.3)    Hematologic 3 (3.4) 
  Postgraduate 29 (33.0)    Bone 2 (2.3) 
      Skin 2 (2.3) 
Employment     Bladder 1 (1.1) 
  Unemployed 22 (25.0)    Eye 1 (1.1) 
  Part time 21 (23.9)    Ovarian 1 (1.1) 
  Full time 45 (51.1)    Not specified 12 (13.6) 
       
Children (Yes)   68 (77.3)  Cancer stage  
       0 2 (2.3) 
Experience of cancer (Yes)   68 (77.3)    I 13 (14.8) 
     II 11 (12.5) 
Previous MH treatment 36 (40.9)    III 23 (26.1) 
Current MH treatment 24 (27.3)    IV 16 (18.2) 
       Not specified 23 (26.1) 
     
   Treatment  
     Surgery 30 (28.3) 
     Surgery and chemotherapy 21 (19.8) 
     Surgery and radiotherapy 9 (8.5) 
      Surgery, chemotherapy and   radiotherapy 27 (25.5) 
     Chemotherapy 9 (8.5) 
     Radiotherapy 4 (3.8) 
     Chemotherapy and radiotherapy 6 (5.7) 
     
Note. MH treatment = Mental health treatment 
 
 
Non-parametric tests indicated that female partners were more anxious than males (U 
= 516.5, p = .004, r = -.31), however no differences reported in depression and FCR. There 
was a statistically significant difference in FCR between different levels of education (H(3) = 
8.59, p = .035). Bonferroni adjusted pairwise comparisons indicated a significant difference 
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between the mean rank FCR score of 54.21 for postgraduates and 33.18 for undergraduates. 
There was also a statistically significant difference in depression score between different 
levels of education (H(3) = 7.99, p = .046). However, there were no differences between 
groups on depression.   
There was a significant difference in FCR between and cancer stages (H(5) = 11.20, p 
= .048). however, Bonferroni adjusted pairwise comparisons indicated there were no 
differences between groups on FCR. No significant differences were found in relation to 
employment status, cancer type or experience of others in network having had cancer.  
 
 
3.2 Correlations 
Intercorrelations and descriptive statistics for independent variables and dependent 
variables are presented in Table 2. Cancer survivor age was negatively correlated with 
depression (rs = -.216), therefore partners in a relationship with younger survivors reported 
greater levels of depressive symptoms. Two metacognitive belief scales, NEG (rs = .499) and 
CSC (rs = .322) were positively associated with FCR. All MCQ-30 subscales were 
significantly positively correlated with anxiety, whilst four out of the five metacognitive 
beliefs domains were significantly positively correlated with depression.  
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Table 2. Descriptive statistics and Spearman's Rho correlations between the study 
independent variables and FCR, anxiety and depression 
              
Variable 2 3 4 5 6 7 8 9 10 11 12 M SD 
1 Survivor age .902*
* 
.646 
*** 
.188 .043 -.122 -.216 
* 
-.194 -.014 -.101 -.211 -.092 53.99 12.29 
 
2 Partner age 
 
 .701*
* 
.190 -.065 -.109 -.190 -.237 -.058 -.161 -.222 -.041 53.35 10.24 
3 Relationship 
length 
  .081 -.057 -.144 -.163 -.190 -.092 .042 -.183 -.134 24.76 13.15 
 
4 Number of 
Children 
   .071 .057 -.067 .000 -.083 -.049 .007 -.136 1.95 1.53 
 
5 FCR     .491 
*** 
.370 
*** 
.168 .499 
*** 
.026 .184 .322** 88.18 10.86 
 
6 HADS-A      .691 
*** 
.254 
* 
.694 
*** 
.237 
* 
.418 
*** 
.396 
*** 
11.02 4.67 
 
7 HADS-D       .154 .623 
*** 
.363 
*** 
.451 
*** 
.280 
** 
7.33 4.64 
 
8 POS        .160 .030 .249* .287 
** 
10.28 4.18 
 
9 NEG         .196 .550 
*** 
.560 
*** 
14.78 5.08 
 
10 CC          .264 
* 
-.096 10.56 4.16 
 
11 NC           .428 
*** 
10.73 3.69 
 
12 CSC           - 14.78 4.15 
              
Note. Relationship length = length of relationship in years, HADS-A = Anxiety, HADS-D = Depression, 
POS = Positive metacognitive belies; NEG = Negative metacognitive beliefs; CC = Cognitive confidence; 
NC = Need to control; CSC = Cognitive self-consciousness; * p < .05; ** p < .01; *** p < .001 
 
3.3 Metacognitive beliefs and FCR, anxiety and depression 
The results of the regression analyses are outlined in Table 3. Multicollinearity was not 
evident between the predictor variables, as variance inflation factors were all less than 2.5 
and tolerance indices ranged from 0.50 to 0.99. In the FCR model, demographic variables 
entered at Step 1 were not significant (F = .352, df = 3, 83, p = .788). Cancer stage entered at 
Step 2 was also non-significant (Fchange = 3.455, df = 1,82, p = .067). After controlling for 
demographic and clinical variables, metacognitive beliefs accounted for an additional 33.0% 
of the variance in FCR (Fchange = 8.247, df = 5,77, p = < .001). The final model accounted for 
38.3% of variance in FCR. Negative beliefs about the uncontrollability and danger of worry 
made independent contributions to the model of FCR (β = .626, p < .001).  
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In the anxiety model, demographic variables entered at Step 1 were significant (F = 
7.787, df = 3,83, p = < .001), accounting for 22.0% of the variance in anxiety. The clinical 
variable, cancer stage, entered at Step 2 was non-significant (Fchange = 2.677, df = 1,82, p = 
.106). Metacognitive beliefs were significant (Fchange = 17.816, df = 5,77, p = < .001), 
accounting for 40.5% of the variance in anxiety. The final model accounted for 65.0% of the 
variance in anxiety. There were three significant predictors in the model, gender (β = -.221, p 
< 0.01), survivor age (β = -.221, p < 0.01) and negative metacognitive beliefs (β = .652, p < 
0.001).  
 
In the depression model, demographic variables entered at Step 1 were significant (F = 
6.140, df = 3,83, p = .001), accounting for 18.2% of the variance in depression. Cancer stage 
entered at Step 2 were non-significant (Fchange = 1.140, df = 1,82, p = .289). Metacognitive 
beliefs entered in the final model, were significant (Fchange = 11.979, df = 5,77, p = < .001), 
accounting for 35.3% of the variance in depression. The final model accounted for 54.6% of 
the variance in depression. Survivor age was a significant predictor of depression (β = -.226, 
p < 0.01). Out of the metacognitive domains, negative beliefs about the uncontrollability and 
danger of worry (β = .488, p < .001) and cognitive confidence (β = .246, p < 0.01), made 
independent contributions to the model of depression. 
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Table 3. Summary of the final models of hierarchical regression predicting FCR, anxiety and 
depression 
 FCR model Anxiety model Depression model 
Variable ∆R2	 β t Sig ∆R2	 β t Sig ∆R2	 β t Sig 
Constant 	  6.040 .000*** 	  2.534 .013* 	  .389 .698 
 	    	    	    
Demographics .013    .220 
*** 
   .182 
*** 
   
  Gender 	 .140 1.358 0.178 	 -.221 -2.855 .006** 	 -.111 -1.262 .211 
  Survivor age 	 .016 .163 .871 	 -.221 -3.033 .003** 	 -.226 -2.721 .008** 
  Education 	 .184 1.855 .067 	 -.071 -.950 .345 	 .114 1.365 .176 
 	    	    	    
Clinical .040    .025    .011    
  Cancer stage 	 .104 1.077 .285 	 .086 1.181 .241 	 .090 1.083 .282 
 	    	    	    
Metacognitive  
domains 
.330 
*** 
   .405 
*** 
   .353 
*** 
   
MCQ-30 POS 	 .135 1.352 .180 	 .074 .982 .329 	 -.048 -.565 .574 
MCQ-30 NEG 	 .626 4.932 .000*** 	 .652 6.818 .000*** 	 .488 4.484 .000*** 
MCQ-30 CC 	 .087 .879 .382 	 .090 1.202 .233 	 .246 2.890 .005** 
MCQ-30 NC 	 -.234 -1.869 .065 	 -.050 -.533 .595 	 .128 1.199 .234 
MCQ-30 CSC 	 .066 .520 .604 	 .017 .176 .861 	 -.080 -.742 .460 
 	    	    	    
Model summary 	    	    	    
R2 .383
*** 
   .650
*** 
   .546
*** 
   
Adjusted R2 .311
*** 
   .609
*** 
   .493
*** 
   
Note. *** p < .001; ** p < .01; * p < .05 
 
4 Discussion 
This is the first study to explore the contribution of metacognitive beliefs to FCR, 
anxiety and depression in partners of cancer survivors. As predicted, metacognitive beliefs 
were positively associated with FCR, anxiety and depression in partners of cancer survivors. 
Furthermore, metacognitive beliefs explained additional variance in FCR, anxiety and 
depression when controlling for demographic and clinical variables, thus confirming the 
second study hypothesis.  
 
4.1 Demographic and clinical characteristics 
Partners in this sample reported greater levels of anxiety and depression if the cancer 
survivor was younger, which may be due to a greater sense of unexpectedness if a person is 
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diagnosed with cancer at a younger age, thus worries about the future and rumination about 
recurrence may be more prominent.  
 
4.2 Metacognitive beliefs and FCR, anxiety and depression 
The S-REF model has been used to explain the development and maintenance of 
various disorders, and different metacognitive beliefs are thought to be prominent in specific 
disorders. According to the model, beliefs about the usefulness of rumination lead both 
directly and indirectly to anxiety and depression. In Generalized Anxiety Disorder (GAD), 
the model gives particular importance to negative beliefs about the uncontrollability of worry 
and the danger of worrying (40). Similarly, the metacognitive model of depression (41, 42) 
suggests that depression results from the activation of perseverative negative thinking and 
unhelpful coping behaviours in response to sadness or negative thoughts. The model also 
proposes that perseverative negative thinking may detract from other aspects of cognition, 
and as a result may decrease confidence in one’s own memory, concentration and attention 
(41). With regards to the theoretical understanding of FCR, it is argued that triggers, 
perceived risk of recurrence and illness uncertainty predict survivor FCR, whilst positive 
beliefs about worrying do not directly predict but act indirectly by increasing maladaptive 
coping (9, 43). 
Out of the metacognitive beliefs that were assessed in this study, negative beliefs about 
the danger and uncontrollability of worry were found to be a significant predictor of FCR, 
anxiety and depression. This is consistent with mental health (44), chronic medical conditions 
(45) and general population (46), whereby negative beliefs about worry were found to be a 
significant contributor to variance in anxiety and depression. Similarly in the cancer 
literature, negative metacognitive beliefs explain additional variance in anxiety, depression 
and trauma in breast or prostate cancer (34), and are associated with heightened FCR in 
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various cancer populations (47-50). It may be that partners of cancer survivors engage in 
negative beliefs about the danger and uncontrollability of worry, which in turn maintains and 
exacerbates unhelpful cognitive processes such as worry, being more vigilant about 
symptoms or avoiding reminders of cancer. This results in the individual feeling unable to 
stop the rumination and worry, therefore the emotional distress is maintained. 
In addition to negative metacognitive beliefs, cognitive confidence was also found to be 
a significant predictor of depression in this sample. This is consistent with the chronic 
medical conditions literature, whereby cognitive confidence is significantly associated with 
psychological and emotional distress, which is argued to negatively affect coping strategies 
when patients feel mentally fatigued (45). Furthermore, currently depressed individuals are 
reported to have lower cognitive confidence (51). Lack of cognitive confidence may be 
associated with increased depressive symptoms in this sample as partners may feel greater 
levels of stress, which could increase rigidity in thinking. Consequently, partners of cancer 
survivors may become reliant on unhelpful coping strategies, which exacerbates and 
maintains depression. 
The findings reported in this study are taken from a mixed cohort with varying ranges 
of cancer type, stage and treatment. This would therefore suggest that it is not necessarily the 
content of thoughts that are problematic, but how someone responds to such thoughts that 
results in FCR and emotional distress. Consequently, the evidence from this study would 
suggest that the transdiagnostic model, S-REF model, is also applicable for partners of cancer 
survivors as well as cancer survivors. The findings also highlight the suitability of the use of 
a universal approach to treating anxiety, depression and FCR in partners of cancer survivors, 
instead of addressing presenting symptoms separately.   
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4.3 Study limitations 
Due to the study being cross-sectional, it is not possible to state whether maladaptive 
metacognitive beliefs are a consequence of FCR, anxiety and depression or a cause, because 
direction of causality cannot be assumed. A prospective study of the model is required in 
order to establish causality.  
Participants self-reported their partners’ diagnosis online; therefore, this could not be 
clinically confirmed. Approximately 15% of the initial data sample were of partners of those 
diagnosed with advanced or recurrent cancer and metastasis. These data had to be excluded 
as this did not meet the inclusion criteria.  
The study reports on data taken from a small sample size consisting of a mixed cohort, 
and as such, the analyses are likely to be underpowered and findings difficult to generalise. 
Larger studies exploring metacognitive beliefs in specific cancer types are warranted to test 
the stability of associations of metacognitive beliefs with FCR, anxiety and depression across 
different tumour populations. 
  
4.4 Clinical implications 
This study is the first example of the application of the S-REF model in partners of 
cancer survivors in order to understand the psychological mechanisms underpinning FCR, 
anxiety and depression. Metacognitive beliefs added to the variance explained in FCR, 
anxiety and depression beyond the contribution made by demographic variables and cancer 
stage, thus suggesting that the way in which a person responds to thoughts is significant in 
the development and maintenance of emotional distress. Consequently, psychological 
interventions that focus on modifiable factors, such as metacognitive beliefs, may be 
effective for this population. Targeting metacognitive beliefs when treating anxiety, 
depression, and FCR have indicated larger post-intervention effects in comparison to 
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traditional cognitive behavioural therapy (52, 53). Given that an interdependent relationship 
exists between emotional distress reported by cancer patients and their partners (54, 55) and 
similar psychological mechanisms underpin distress experienced by cancer patients, there is 
an argument for interventions based on this model to be delivered jointly to both cancer 
patient and partner. By delivering interventions based on a transdiagnostic model of 
emotional distress, this would offer a much more effective time-efficient approach, as 
difficulties could be addressed simultaneously rather than treatments delivered separately. 
Future research should endeavour to strengthen the evidence base and prospectively 
explore the role of metacognitive beliefs in partners of cancer survivors, whilst controlling 
for baseline levels of FCR, anxiety, depression, clinical variables and cancer stage. Research 
could consider the contribution of illness perceptions, to investigate whether metacognitive 
beliefs continue to significantly explain additional variance in FCR, anxiety and depression 
when both theoretical frameworks are included in a regression model. Intervention studies are 
also required in order to assess the potential efficacy of targeting and modifying negative 
metacognitive beliefs against traditional cognitive behavioural approaches. 
 
4.5 Conclusion 
The findings from this study supports the prediction from the S-REF model that 
metacognitive beliefs explain additional variance in FCR and emotional distress, when 
controlling for demographic and clinical variables. Consequently, the S-REF model offers an 
alternative understanding of the psychological mechanisms involved in emotional distress in 
partners of cancer survivors, which may be useful for consideration in the design of future 
interventions. However, further research is warranted in order to build upon these findings, 
specifically longitudinal studies are necessary to determine a causal role for metacognitive 
beliefs in anxiety and depression. Intervention studies also need to evaluate the potential 
efficacy of metacognitive therapy in alleviating anxiety, depression, FCR experienced by 
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partners of cancer survivors. This study offers preliminary evidence for the utility of the S-
REF model in understanding the experiences of partners of survivors, which may help to 
inform more targeted treatments for this population. 
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reference to the text. All abbreviations must be defined in footnotes. Footnote symbols: †, ‡, 
§, ¶, should be used (in that order) and *, **, *** should be reserved for P-values. Statistical 
measures such as SD or SEM should be identified in the headings. 
• Figure Legends 
Legends should be concise but comprehensive – the figure and its legend must be 
understandable without reference to the text. Include definitions of any symbols used and 
define/explain all abbreviations and units of measurement. 
• Appendices 
Appendices will be published after the references. For submission they should be supplied as 
separate files but referred to in the text.  
 
 
Further details can be accessed on the Psycho-Oncology website: 
https://onlinelibrary.wiley.com/page/journal/10991611/homepage/forauthors.html 
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Appendix B. Data extraction form 
 
Author: 
 
Year of publication: 
 
Title: 
 
Location: 
 
Study design Cross-sectional:  
Longitudinal:  Follow-up length  
Sample number  
Sample number 
in analyses 
 
Caregiver 
demographics: 
 
 
Age: Gender: Ethnicity: Education: Relationship 
length: 
Clinical and 
treatment 
characteristics of 
survivor 
 
Diagnosis 
stage: 
Time since 
diagnosis/treatment: 
Treatment type: 
Main findings  
 
Study outcomes  
 
Outcomes and 
predictors 
 
 
 
Analyses  
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Appendix C. Email correspondence from authors (removed for confidentiality purposes) 
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Appendix D. Quality assessment tool 
 
William’s Tool: Quality assessment of observational studies 
 
Grade each criterion as “Yes”, “No”, “Partially” or “Unclear”. 
Factors to consider when making an assessment are listed under each criterion.  Where 
appropriate (particularly when assigning a “No”, “Partially” or “Can’t tell” score), please 
provide a brief rationale for your decision (in parantheses) in the evidence table. 
Criteria marked italics are considered the most essential quality indicators for our purposes. 
 
1) Unbiased selection of the cohort? 
Factors that help reduce selection bias:  
- Prospective study design and recruitment of subjects 
- Inclusion/exclusion criteria clearly described (especially re age, cancer 
diagnosis/survivorship status) 
- Assessed using valid and reliable measures 
- Recruitment strategy clearly described 
- Relatively free from bias (selection bias might be introduced e.g., by recruitment via 
advertisement) 
 
2) Sample size calculated/5% difference? 
Factors to consider: 
- Did the authors report conducting a power analysis or describe some other basis for 
determining the adequacy of study group sizes for the primary outcome(s) of interest 
to us? 
- Was the sample size sufficiently large to detect a clinically significant difference of 
5% in event rates or an OR/RR increase of  ≥ 1.5 or decrease of ≥ 0.67 between 
groups in at least one primary outcome measure of interest to us? 
 
3) Adequate description of the cohort? 
Consider whether the cohort is well-characterized in terms of baseline: 
- Age 
- Sex 
- Race  
- Educational level 
- Cancer type, stage other medical factors? 
 
4) Validated method for assessing predictor/outcome variables? 
Factors to consider: 
- Was the method used to assess predictor/outcomes variables clearly described? 
(Details should be sufficient to permit replication in new studies). 
- Was a valid and reliable measure used to assess predictor/outcome variables? 
(Subjected measures based on self-report tend to have lower reliability and validity 
than objective measures such as clinical reports and lab findings). 
  
5) Validated method for assessing fear of cancer recurrence? 
Factors to consider: 
- Were primary outcomes (fear of cancer recurrence) assessed using valid and reliable 
measures? 
- Were these measures implemented consistently across all study participants? 
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6) Adequate follow-up period? 
Factors to consider: 
- Minimum adequate follow-up period is X for survivorship?  Check this. 
- Follow-up period should be the same for all groups 
- In cohort studies, length of follow-up should be the same across all groups 
 
7) Missing data minimal? 
Factors to consider: 
- Did attrition from any group exceed 30% (Attrition is measured in relation to the time 
between baseline/allocation and outcome measurement.  Where different numbers of 
patients are followed up for different outcomes, use the number followed up for the 
primary outcome for this calculation). 
- Did attrition differ between groups by more than 10%? 
 
8) Confounders controlled for? 
Factors to consider: 
- Did the analysis control for any baseline differences between groups? 
- Does the study identify and control for important confounding variables and effect 
modifiers? (Confounding variables are risk factors that are correlated with the 
intervention/exposure and outcome and may therefore bias the estimation of the effect 
of intervention/exposure on outcome if unmeasured.  Effect modifiers are not 
correlated with the intervention/exposure, but change the effect of the 
intervention/exposure on the outcome.  Age, race/ethnicity, education and measures 
of SES are examples of effect modifiers and confounding variables for the exposures 
and outcomes of interest in this study). 
 
9) Analytic methods appropriate? 
Factors to consider: 
- Was the kind of analysis done appropriate for the kind of outcome data? 
- Dichotomous – logistic regression, survival 
- Categorical – mixed model for categorical outcomes 
- Continuous – ANCOVA, mixed model 
- Was the analysis done on an intention-to-treat basis? (That is, was the impact of loss 
to follow-up [or differential loss to follow-up] assessed, e.g., through sensitivity 
analysis or another intent-to-treat adjustment method? 
- Was the number of variables used in the analysis appropriate for the sample size? 
(The statistical technique used must be appropriate to the data and take into account 
issues such as controlling for small sample size, clustering, rare outcomes, multiple 
comparison and number of covariates for a given sample size.  The multiple 
comparisons issue may be a problem particularly when performance results on 
numerous cognitive measures are being compared.  When assessing change on 
cognitive measure over time, consider whether change score should be adjusted for 
baseline score, and consider distribution of baseline scores and change scores). 
 
     • The multiple comparisons issue may be a problem particularly when performance results 
on numerous cognitive measures are being compared. When assessing change on cognitive 
measure over time, consider whether change score should be adjusted for baseline score, and 
consider distribution of baseline scores and change scores.) •  
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Appendix E. Participant information sheet 
 
 
v3. 08.04.2019 
 
 
 
 
 
 
Worry in partners of cancer survivors 
 
You are being invited to participate in a research study.  Before you decide whether to participate, it is 
important for you to understand why the research is being done and what it will involve.  Please take 
time to read the following information carefully and feel free to ask us if you would like more information 
or if there is anything that you do not understand.  Please also feel free to discuss this with your friends, 
relatives and GP if you wish.  We would like to stress that you do not have to accept this invitation and 
should only agree to take part if you want to. 
 
Thank you for reading this. 
 
 
1. What is the purpose of this study? 
Fear of cancer recurrence is a commonly reported concern by cancer survivors and their partners, with 
partners tending to worry more about the possibility of cancer returning than cancer patients do 
themselves.  Previous research has looked into the factors that may influence fear of cancer recurrence 
among cancer survivors, however much less is known about partners of cancer survivors.  The aim of 
this study is to better understand how psychological factors can contribute to worry in partners of cancer 
survivors. 
 
2. Why have I been chosen to take part? 
You have been asked to take part, as you are a partner of someone who has had cancer.  We are 
hoping to recruit 150 participants both online (via social media and specialist local and national cancer 
charity websites) and at local support groups.  
 
3. Do I have to take part? 
You do not have to take part in the study.  If you do decide to participate, you are free to stop completing 
the survey at any time without needing to provide an explanation to the research team.  As the survey 
does not contain personal identifiable information, it is not possible to withdraw the responses that you 
have already submitted.  The responses that you have provided may be included within the study 
analysis.  
4. What will happen if I take part? 
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You will be asked to complete a survey online, which will take approximately 20 minutes.  The survey 
will consist of various questions, which will look at emotional distress, fear of cancer recurrence, and 
beliefs about illness and worry.  The data collected from the survey will not contain any personal 
identifiable information, however personal data (such as a telephone number or email address) will be 
requested if you wish to enter a prize draw after completing the survey.   
If you do wish to be entered into a prize draw to win one of six £25 high street vouchers, you will be 
asked to provide your name and contact details (telephone number or email address).  These details 
will be stored separately from the questionnaire data, and will not be linked to the responses that you 
have provided in the survey.   
 
The researchers involved this study are Louise O’Rourke, Trainee Clinical Psychologist and 
supervisors, Dr Peter Fisher, Dr Gemma Cherry and Dr Sophie Campbell.   
 
5. How will my data be used? 
The study will offer an optional prize draw which will require participants to provide personal information 
(contact details such as telephone number or email address).  The University processes personal data 
as part of its research and teaching activities in accordance with the lawful basis of ‘public task’, and in 
accordance with the University’s purpose of “advancing education, learning and research for the public 
benefit”. 
 
Under UK data protection legislation, the University acts as the Data Controller for personal data 
collected as part of the University’s research.  The Chief Investigator acts as the Data Processor for 
this study, and any queries relating to the handling of your personal data can be sent to Dr Peter Fisher 
(plfisher@liverpool.ac.uk, tel.: 0151 794 4106). 
 
Further information on how your data will be used can be found in the table below. 
How will my data be collected? Online 
How will my data be stored? On a password-protected computer 
How long will my data be stored 
for? 
10 years 
What measures are in place to 
protect the security and 
confidentiality of my data? 
Data will be stored securely on the University of Liverpool 
computer drive, on a password-protected computer.  
Data will not contain personal identifiable information, and 
participant contact details will be stored on a separate 
password-protected file on the University of Liverpool 
computer drive.  Contact details will be deleted within one 
month of winners of the prize draw being announced.   
Will my data be anonymised? Yes 
How will my data be used? For the purpose of a Doctorate of Clinical Psychology 
thesis, and publication in academic journal. 
Who will have access to my 
data? 
Named researchers in the investigatory team (details are 
listed at the end). 
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Will my data be archived for use 
in other research projects in the 
future? 
No 
How will my data be destroyed? After 10 years data will be disposed of confidentially and 
deleted from all stored locations (University of Liverpool 
secure networked computer drive). 
 
6. Are there any risks in taking part? 
Due to the sensitive nature of the research topic, you may find some of the questions included in the 
survey distressing.  There will be some questions that will ask you about your mental health, specifically 
if you have received treatment for difficulties with low mood or anxiety.  Some questions will ask you 
about your partner’s cancer diagnosis, e.g., “Minor aches and pains of my family member remind me 
of his/her illness”, and “I am concerned that the difficulties with my family member’s illness may not be 
over”.  You can abstain from answering any questions that you may be uncomfortable with.   
 
Should you experience any discomfort as part of the research, please speak with your GP, or contact 
Macmillan cancer support line on 0808 808 00 00.  The Macmillan cancer support line is free of charge 
to phone and is open 7 days a week, from 8am – 8pm.  Further details can be found on the Macmillan 
website (https://www.macmillan.org.uk/information-and-support/coping/getting-support/talking-to-
us/macmillan-support-line.html).  Should you wish to speak with someone when the Macmillan cancer 
support line is closed, the Samaritans phone line (116 123) is open 24 hours a day. 
 
You can also search online for local NHS cancer information and support services 
(https://www.nhs.uk/service-search/Cancer-information-and-support/LocationSearch/320). 
 
7. Are there any benefits in taking part? 
There are no direct benefits in participating in this research project.  However through taking part in the 
study, you will be contributing to current research and furthering our understanding as to why some 
individuals may experience greater levels of fear of cancer recurrence.  This in turn may help to improve 
the support already available to partners of cancer survivors, through identifying psychological factors 
that may enhance interventions. 
 
8. What will happen to the results of the study? 
The results of the study will be used to inform academic publications, including a Doctorate in Clinical 
Psychology research thesis and publication in a peer-reviewed academic journal.  You will be asked to 
indicate on the consent form if you wish to be informed of the research findings.  As the data taken from 
the questionnaire will be anonymised, you will not be identifiable from the results.  
 
 
 
9. What will happen if I want to stop taking part? 
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You can stop answering the survey questions at any time.  However, as the survey does not contain 
personal identifiable information, it is not possible to withdraw the responses that you have already 
submitted.  The responses that you have provided may be included within the study analysis.  
 
10. What if I am unhappy or if there is a problem? 
If you are unhappy, or if there is a problem, please feel free to let us know by contacting the Chief 
Investigator, Dr Peter Fisher, 0151 794 4106, and we will try to help.  If you remain unhappy or have a 
complaint that you feel you cannot come to us with, then you should contact the Research Ethics and 
Integrity Office at ethics@liv.ac.uk.  When contacting the Research Ethics and Integrity Office, please 
provide details of the name or description of the study (so that it can be identified), the researchers 
involved, and the details of the complaint you wish to make. 
 
The University strives to maintain the highest standards of rigour in the processing of your data.  
However, if you have any concerns about the way in which the University processes your personal data, 
it is important that you are aware of your right to lodge a complaint with the Information Commissioner’s 
Office by calling 0303 123 1113. 
 
11. Who can I contact if I have further questions? 
Chief Investigator: 
Dr Peter Fisher 
University of Liverpool, School of Psychology, Whelan Building, Liverpool, L69 3GB 
Tel: 0151 794 4106 
 
Contact details of investigatory team:  
Louise O’Rourke, Trainee Clinical Psychologist l.o-rourke@liverpool.ac.uk 
 
Dr Gemma Cherry 
 
Dr Sophie Campbell 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
98 
Appendix F. Consent form 
 
 
 
 
 
Participant consent form 
 
Version number & date: v3 13.04.2019 
Research ethics approval number:  
Title of the research project: Worry in partners of cancer survivors 
Name of researcher(s): Louise O’Rourke, Dr Peter Fisher, Dr Gemma Cherry, Dr Sophie Campbell 
 
 Please tick box 
1. I confirm that I have read and have understood the information sheet dated (DATE) for 
the above study.  I have had the opportunity to consider the information, ask questions and 
have had these answered satisfactorily. 
 
 
2. I understand that my participation is voluntary and that I am free to stop completing the 
survey at any time without giving any reason and without my rights being affected.  
However, as the survey does not contain personal identifiable information, it is not possible 
to withdraw the responses that I have already submitted.  The responses that I have provided 
may be included within the study analysis. 
 
 
3. I understand that I will not be identified or identifiable in the report or reports that result 
from the research. 
 
 
4. I understand that survey data will be stored in the University of Liverpool, and members 
of the research team will have access to the data for up to 10 years. 
 
 
5. I agree to take part in the above study. 
 
 
 
6. I understand that the information I have submitted will be used to inform academic 
publications, including a Doctorate in Clinical Psychology research thesis and publication in 
a peer-reviewed academic journal. 
 
 
 
7. Please tick the box if you would like to receive general feedback of the study.  A page at 
the end of the survey will ask you to provide contact details in order for us to send you the 
feedback. 
 
 
 
 
      
Principal Investigator 
Dr Peter Fisher 
University of Liverpool 
School of Psychology 
Whelan Building 
Liverpool 
L69 3GB 
0151 794 4106 
plfisher@liverpool.ac.uk 
Student Investigator 
Louise O’Rourke 
University of Liverpool 
School of Psychology 
Whelan Building 
Liverpool 
L69 3GB 
0151 794 5530 
l.o-rourke@liverpool.ac.uk 
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Appendix G. Ethics approval letter 
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Doctorate	of	Clinical	Psychology	Doctorate	Programme		
University	of	Liverpool		
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Appendix H. Research advert 
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Appendix I. Debrief sheet 
 
v3. 08.04.2019 
 
 
 
 
Worry in partners of cancer survivors 
 
Participant Debrief sheet 
 
 
Thank you for participating in the present study, which examined your experiences as 
a partner of a cancer survivor.  The study was attempting to discover more about how 
psychological factors can contribute to distress and worry in partners of cancer 
survivors.  As partners are often neglected, the hope of this research is to better 
understand how people cope when faced with worries of their partner’s cancer 
diagnosis.  
 
We hope that you have found participating in the study interesting.  Your survey 
responses are anonymous and you will not be identifiable from the results.  If you did 
provide your contact details (telephone number or email address) in order to enter the 
prize draw, these details will be stored separately from the survey data and will not be 
linked to the responses that you have provided in the survey.  If you have any 
questions regarding the research, please feel free to contact one of the researchers: 
  
Louise O’Rourke, Student Investigator 
l.o-rourke@liverpool.ac.uk 
 
Dr Peter Fisher, Chief Investigator  
plfisher@liverpool.ac.uk 
 
Should you experience any discomfort as part of the research, please speak with your 
GP, or contact Macmillan cancer support line on 0808 808 00 00.  Lines are open 7 
days week, from 8am – 8pm.  Further details can be found on the Macmillan website: 
https://www.macmillan.org.uk/information-and-support/coping/getting-support/talking-
to-us/macmillan-support-line.html).   
Should you wish to speak with someone urgently outside of these hours, please 
contact the Samaritans on 116 123. 
 
Information can also be found on the NHS website, including links to specialist cancer 
support services: https://www.nhs.uk/conditions/cancer/. 
 
Thank you again for your participation. 
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Appendix J. Fear of Recurrence Questionnaire 
 
FAMILY MEMBER VERSION 
 
INSTRUCTIONS: 
 
The following 22 questions are designed to find out what you think about some health-related 
matters.  There are no “right” or “wrong” answers; this is not a test but rather a questionnaire 
asking for your opinion. 
 
Work at a fairly high speed through this questionnaire, and do not be concerned about 
whether or not your answers are consistent.  It is your first impression that is desired.  On the 
other hand, please do not be careless as it is your true impression that we want. 
 
CHECK THE ANSWER WHICH BEST TYPIFIES YOUR RESPONSE TO THE STATEMENT 
 
  
Strongly 
Agree Agree Neutral Disagree 
Strongly 
Disagree 
1. I think about my family member’s health often.      
2. I am bothered by the uncertainty of my family 
member’s health status. 
     
3. I think more about my family member’s health 
now than before his/her illness was diagnosed. 
     
4. My family member has no physical concerns at 
this time. 
     
5. I worry no more about my family member’s 
health than other people worry about their 
family’s health. 
     
6. I feel there is little need to worry about my 
family member’s future health status. 
     
7. I always take my family member’s health into 
consideration when making future plans. 
     
8. Compared to other families where a member 
has this illness, I feel that I worry less than they 
do about health concerns. 
     
9. My family member’s future health status is not 
a major concern of mine. 
     
10. I sometimes find myself preoccupied with my 
family member’s physical condition. 
     
11. Just prior to my family member’s regularly 
scheduled exams, my uneasiness about his/her 
health increases. 
     
12. I think no more about my family member’s 
health presently than I did before his/her illness 
was diagnosed. 
     
13. I am not bothered by uncertainty regarding my 
family member’s health status. 
     
14. I would like to feel more certain about my 
family member’s health. 
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15. I seldom think about my family member’s 
health. 
     
16. Because of my family member’s physical 
health, his/her future is of concern to me. 
     
17. I do not worry about my family member’s 
illness returning. 
     
18. When I think about my family member’s future 
health status, I feel some uneasiness. 
     
19. Minor aches and pains of my family member 
remind me of his/her illness. 
     
20. I feel optimistic as I focus on my family 
member’s future. 
     
21. I am concerned that the difficulties with my 
family member’s illness may not be over. 
     
22. I do not feel anxious about my family 
member’s future when I read articles about 
his/her illness. 
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Appendix K. Hospital Anxiety and Depression Scale 
 
  
 
 
 
 
 
 
Hospital Anxiety and Depression Scale (HADS) 
 
Tick the box beside the reply that is closest to how you have been feeling in the past week. 
Don’t take too long over you replies: your immediate is best. 
D A  D A  
  I feel tense or 'wound up':   I feel as if I am slowed down: 
 3 Most of the time 3  Nearly all the time 
 2 A lot of the time 2  Very often 
 1 From time to time, occasionally 1  Sometimes 
 0 Not at all 0  Not at all 
      
  I still enjoy the things I used to 
enjoy: 
  I get a sort of frightened feeling like 
'butterflies' in the stomach: 
0  Definitely as much  0 Not at all 
1  Not quite so much  1 Occasionally 
2  Only a little  2 Quite Often 
3  Hardly at all  3 Very Often 
      
  I get a sort of frightened feeling as if 
something awful is about to 
happen: 
  
I have lost interest in my appearance: 
 3 Very definitely and quite badly 3  Definitely 
 2 Yes, but not too badly 2  I don't take as much care as I should 
 1 A little, but it doesn't worry me 1  I may not take quite as much care 
 0 Not at all 0  I take just as much care as ever 
      
  I can laugh and see the funny side 
of things: 
  I feel restless as I have to be on the 
move: 
0  As much as I always could  3 Very much indeed 
1  Not quite so much now  2 Quite a lot 
2  Definitely not so much now  1 Not very much 
3  Not at all  0 Not at all 
  Worrying thoughts go through my 
mind: 
  I look forward with enjoyment to 
things: 
 3 A great deal of the time 0  As much as I ever did 
 2 A lot of the time 1  Rather less than I used to 
 1 From time to time, but not too often 2  Definitely less than I used to 
 0 Only occasionally 3  Hardly at all 
      
  I feel cheerful:   I get sudden feelings of panic: 
3  Not at all  3 Very often indeed 
2  Not often  2 Quite often 
1  Sometimes  1 Not very often 
0  Most of the time  0 Not at all 
      
  I can sit at ease and feel relaxed:   I can enjoy a good book or radio or TV 
program: 
 0 Definitely 0  Often 
 1 Usually 1  Sometimes 
 2 Not Often 2  Not often 
 3 Not at all 3  Very seldom 
Please check you have answered all the questions 
 
Scoring:  
Total score: Depression (D) ___________ Anxiety (A) ______________ 
0-7  = Normal 
8-10  = Borderline abnormal (borderline case) 
11-21  = Abnormal (case) 
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Appendix L. Demographic and clinical information 
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Appendix M: Metacognitions Questionnaire-30  
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Appendix N: Cognitive Attentional Scale-1 
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Appendix O: SPSS data output 
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